Abstract
The chapter on the gastrointestinal tract focuses on neoplasms arising in the esophagus, stomach, small intestine, appendix, colon, and anus. An overview of concepts common to the gastrointestinal tract, such as neoplasia arising in inflammatory conditions and hereditary conditions, and an overview of neuroendocrine neoplasms, is provided in the introductory section. A brief review of normal histology of the organs is presented. Most of the tumors presented in this chapter represent epithelial neoplasms, and thus, mesenchymal tumors and lymphomas are reviewed in their respective chapters. The features of the neoplasms are presented, including descriptions of pertinent precursor lesions, pathogenesis, macroscopic and microscopic features as well as tumor subtypes and histologic prognostic features, and immunohistochemical profiles. Common diagnostic dilemmas, predictive and prognostic factors, and molecular abnormalities are discussed. Changes to the current American Joint Commission on Cancer staging guidelines are highlighted.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.
O’Sullivan KE, Phelan JJ, O’Hanlon C, Lysaght J, O’Sullivan JN, Reynolds JV. The role of inflammation in cancer of the esophagus. Expert Rev Gastroenterol Hepatol. 2014;8(7):749–60.
Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev. 2015;20(1):25–40.
Correa P, Piazuelo MB. Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev. 2011;7(1):59–64.
Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807–16.
Axelrad JE, Lichtiger S, Sethi A. Treatment of Crohn’s disease anastomotic stricture with a Lumen-apposing metal stent. Clin Gastroenterol Hepatol. 2018;16(3):A25–6.
Ng DW, Ching Tan GH, Teo MC. Malignancy arising in a 41-year-old colonic interposition graft. Asian J Surg. 2016;39(1):45–7.
Iwamoto M, Kawada K, Hida K, Hasegawa S, Sakai Y. Adenocarcinoma arising at a colostomy site with inguinal lymph node metastasis: report of a case. Jpn J Clin Oncol. 2015;45(2):217–20.
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–87. e3.
Tutlewska K, Lubinski J, Kurzawski G. Germline deletions in the EPCAM gene as a cause of lynch syndrome – literature review. Hered Cancer Clin Pract. 2013;11(1):9.
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Am J Gastroenterol. 2014;109(8):1159–79.
Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on hereditary non-polyposis colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424–5.
Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453–6.
Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60(7):950–7.
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.
Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2017;141(5):625–57.
Network NCC. Colon cancer (Version 2.2017 – March 13, 2017). Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
Network NCC. Rectal cancer (Version 3.2017 – March 13, 2017). Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
Evaluation of Genomic Applications in P, Prevention Working G. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35–41.
Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69–79.
Rubenstein JH, Enns R, Heidelbaugh J, Barkun A, Clinical Guidelines C. American Gastroenterological Association Institute guideline on the diagnosis and management of Lynch syndrome. Gastroenterology. 2015;149(3):777–82. quiz e16–7.
Bartley AN, Luthra R, Saraiya DS, Urbauer DL, Broaddus RR. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila). 2012;5(2):320–7.
Blake C, Tsao JL, Wu A, Shibata D. Stepwise deletions of polyA sequences in mismatch repair-deficient colorectal cancers. Am J Pathol. 2001;158(5):1867–70.
Kuan SF, Ren B, Brand R, Dudley B, Pai RK. Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression. Hum Pathol. 2017;63:33–9.
Bao F, Panarelli NC, Rennert H, Sherr DL, Yantiss RK. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol. 2010;34(12):1798–804.
Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10(4):293–300.
Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. 2008;10(4):301–7.
Buhard O, Lagrange A, Guilloux A, Colas C, Chouchene M, Wanherdrick K, et al. HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. J Med Genet. 2016;53(6):377–84.
Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30(7):1015–6.
Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem. 2014;60(9):1192–9.
Nowak JA, Yurgelun MB, Bruce JL, Rojas-Rudilla V, Hall DL, Shivdasani P, et al. Detection of mismatch repair deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing. J Mol Diagn. 2017;19(1):84–91.
Funkhouser WK Jr, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn. 2012;14(2):91–103.
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–57.
Deschoolmeester V, Baay M, Wuyts W, Van Marck E, Van Damme N, Vermeulen P, et al. Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. J Mol Diagn. 2008;10(2):154–9.
Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, Zapater P, Castillejo A, Barbera VM, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013;144(5):926–32 e1. quiz e13–4.
Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014;147(6):1308–16. e1.
Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014;146(3):643–6. e8.
Castillejo A, Vargas G, Castillejo MI, Navarro M, Barbera VM, Gonzalez S, et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J Cancer. 2014;50(13):2241–50.
Morak M, Heidenreich B, Keller G, Hampel H, Laner A, de la Chapelle A, et al. Biallelic MUTYH mutations can mimic lynch syndrome. Eur J Hum Genet. 2014;22(11):1334–7.
Carethers JM. Differentiating Lynch-like from Lynch syndrome. Gastroenterology. 2014;146(3):602–4.
Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. 2015;21(31):9253–61.
Shia J. Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Semin Diagn Pathol. 2015;32(5):352–61.
Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer. 2014;50(5):987–96.
Jasperson K, Burt RW. The genetics of colorectal cancer. Surg Oncol Clin N Am. 2015;24(4):683–703.
Newton KF, Mallinson EK, Bowen J, Lalloo F, Clancy T, Hill J, et al. Genotype-phenotype correlation in colorectal polyposis. Clin Genet. 2012;81(6):521–31.
Knudsen AL, Bulow S, Tomlinson I, Moslein G, Heinimann K, Christensen IJ, et al. Attenuated familial adenomatous polyposis: results from an international collaborative study. Colorectal Dis. 2010;12(10 Online):e243–9.
Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology. 2004;127(2):444–51.
Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet. 2004;12(1):52–8.
Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53(3):381–6.
Gardner EJ. Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. Am J Hum Genet. 1962;14:376–90.
Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137(6):1976–85. e1–10.
Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol. 2011;79(1):1–16.
Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. Inherited variants of MYH associated with somatic G:C-->T:a mutations in colorectal tumors. Nat Genet. 2002;30(2):227–32.
Borras E, Taggart MW, Lynch PM, Vilar E. Establishing a diagnostic road map for MUTYH-associated polyposis. Clin Cancer Res. 2014;20(5):1061–3.
Guarinos C, Juarez M, Egoavil C, Rodriguez-Soler M, Perez-Carbonell L, Salas R, et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clin Cancer Res. 2014;20(5):1158–68.
Church J, Kravochuck S. The “studded” rectum: phenotypic evidence of MYH-associated polyposis. Dis Colon Rectum. 2016;59(6):565–9.
Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136–44.
Bellido F, Pineda M, Aiza G, Valdes-Mas R, Navarro M, Puente DA, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325–32.
Mehenni H, Blouin JL, Radhakrishna U, Bhardwaj SS, Bhardwaj K, Dixit VB, et al. Peutz-Jeghers syndrome: confirmation of linkage to chromosome 19p13.3 and identification of a potential second locus, on 19q13.4. Am J Hum Genet. 1997;61(6):1327–34.
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998;18(1):38–43.
Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R, et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell. 2001;7(6):1307–19.
Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem. 2006;75:137–63.
Jass JR, Williams CB, Bussey HJ, Morson BC. Juvenile polyposis--a precancerous condition. Histopathology. 1988;13(6):619–30.
Bouraoui S, Azouz H, Kechrid H, Lemaiem F, Mzabi-Regaya S. Peutz-Jeghers’ syndrome with malignant development in a hamartomatous polyp: report of one case and review of the literature. Gastroenterol Clin Biol. 2008;32(3):250–4.
Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139(6):1927–33.
Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59(7):975–86.
Gammon A, Jasperson K, Kohlmann W, Burt RW. Hamartomatous polyposis syndromes. Best Pract Res Clin Gastroenterol. 2009;23(2):219–31.
Menko FH, Kneepkens CM, de Leeuw N, Peeters EA, Van Maldergem L, Kamsteeg EJ, et al. Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes. Clin Genet. 2008;74(2):145–54.
Brosens LA, van Hattem A, Hylind LM, Iacobuzio-Donahue C, Romans KE, Axilbund J, et al. Risk of colorectal cancer in juvenile polyposis. Gut. 2007;56(7):965–7.
Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22(3):183–98.
Eng C, Thiele H, Zhou XP, Gorlin RJ, Hennekam RC, Winter RM. PTEN mutations and proteus syndrome. Lancet. 2001;358(9298):2079–80.
Stanich PP, Owens VL, Sweetser S, Khambatta S, Smyrk TC, Richardson RL, et al. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc. 2011;86(6):489–92.
Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol. 2012;18(37):5171–80.
Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24(12):3040–4.
AJCC cancer staging manual. 8 ed. New York: Springer Science+Business Media; 2016. pages cm p.
Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008;13(12):1255–69.
Raut CP, Kulke MH, Glickman JN, Swanson RS, Ashley SW. Carcinoid tumors. Curr Probl Surg. 2006;43(6):383–450.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
Williams ED, Siebenmann RE, Sobin LH. Histological typing of endocrine tumours. 1st ed. Geneva: World Health Organization. International Histological Classification of Tumours; 1980. p. 69.
Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. 2nd ed. Berlin Heidelberg: Springer; 2000.
Hamilton SR, Aaltonen LA, Organization WH, Cancer IAfRo. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.
Lloyd RV, Osamura R, Kloppel G, Rosai J, editors. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010. p. 417.
Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012;36(12):1761–70.
Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol. 2015;28(5):686–94.
Adsay V. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. Am J Surg Pathol. 2012;36(12):1743–6.
McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol. 2013;37(11):1671–7.
Matsukuma K, Olson KA, Gui D, Gandour-Edwards R, Li Y, Beckett L. Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors. Mod Pathol. 2017;30(4):620–9.
Benafif S, Eeles R. Diagnosis and management of hereditary carcinoids. Recent Results Cancer Res. 2016;205:149–68.
Sei Y, Zhao X, Forbes J, Szymczak S, Li Q, Trivedi A, et al. A hereditary form of small intestinal carcinoid associated with a germline mutation in inositol polyphosphate multikinase. Gastroenterology. 2015;149(1):67–78.
Katdare MV, Fichera A, Heimann TM. Familial rectal carcinoid: report of two first-degree relatives with rectal carcinoid and review of the literature. Tech Coloproctol. 2006;10(2):143–6.
Doi M, Ikawa O, Taniguchi H, Kawamura T, Katsura K. Multiple rectal carcinoid tumors in monozygotic twins. Clin J Gastroenterol. 2016;9(4):215–21.
Hiripi E, Bermejo JL, Sundquist J, Hemminki K. Familial gastrointestinal carcinoid tumours and associated cancers. Ann Oncol. 2009;20(5):950–4.
Hassan C, Repici A, Rex DK. Serrated polyposis syndrome: risk stratification or reduction? Gut. 2016;65(7):1070–2.
Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64.
Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649–57.
Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist. 2016;21(10):1191–9.
Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogeneous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683–90.
Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol. 2014;25(1):65–79.
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.
Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–202.
Smith JD, Reidy DL, Goodman KA, Shia J, Nash GM. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014;21(9):2956–62.
Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–62.
Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25(2):186–92.
La Rosa S, Marando A, Sessa F, Capella C. Mixed adenoneuroendocrine carcinomas (MANECs) of the gastrointestinal tract: an update. Cancers (Basel). 2012;4(1):11–30.
La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012;36(4):601–11.
Capella C, La Rosa S, Uccella S, Billo P, Cornaggia M. Mixed endocrine-exocrine tumors of the gastrointestinal tract. Semin Diagn Pathol. 2000;17(2):91–103.
Volante M, Rindi G, Papotti M. The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch. 2006;449(5):499–506.
Lewin K. Carcinoid tumors and the mixed (composite) glandular-endocrine cell carcinomas. Am J Surg Pathol. 1987;11(Suppl 1):71–86.
Volante M, Righi L, Asioli S, Bussolati G, Papotti M. Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms. Virchows Arch. 2007;451(Suppl 1):S61–9.
Hervieu V, Scoazec JY. Mixed endocrine tumors. Ann Pathol. 2005;25(6):511–28.
Weissferdt A, Tang X, Wistuba II, Moran CA. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1. Mod Pathol. 2013;26(12):1554–60.
Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol. 2007;15(4):407–14.
Ordonez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012;19(3):140–51.
Graham RP, Shrestha B, Caron BL, Smyrk TC, Grogg KL, Lloyd RV, et al. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases. Am J Surg Pathol. 2013;37(3):399–405.
Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol. 2008;32(3):420–5.
Agaimy A, Erlenbach-Wunsch K, Konukiewitz B, Schmitt AM, Rieker RJ, Vieth M, et al. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol. 2013;26(7):995–1003.
Yang EJ, Kong CS, Longacre TA. Vulvar and anal intraepithelial neoplasia: terminology, diagnosis, and ancillary studies. Adv Anat Pathol. 2017;24(3):136–50.
Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D. Value of islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol. 2012;25(6):893–901.
Mehta RS, Song M, Nishihara R, Drew DA, Wu K, Qian ZR, et al. Dietary patterns and risk of colorectal cancer: analysis by tumor location and molecular subtypes. Gastroenterology. 2017;152(8):1944–53. e1.
Kim JY, Hong SM. Recent updates on neuroendocrine tumors from the gastrointestinal and Pancreatobiliary tracts. Arch Pathol Lab Med. 2016;140(5):437–48.
Kim KW, Krajewski KM, Nishino M, Jagannathan JP, Shinagare AB, Tirumani SH, et al. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR Am J Roentgenol. 2013;201(4):811–24.
Koo J, Dhall D. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy? Semin Diagn Pathol. 2015;32(6):456–68.
Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–97.
Dogeas E, Cameron JL, Wolfgang CL, Hirose K, Hruban RH, Makary MA, et al. Duodenal and ampullary carcinoid tumors: size predicts necessity for lymphadenectomy. J Gastrointest Surg. 2017;21(8):1262–9.
Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184–7.
Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–37.
Wang HH, Mangano MM, Antonioli DA. Evaluation of T-lymphocytes in esophageal mucosal biopsies. Mod Pathol. 1994;7(1):55–8.
De La Pava S, Nigogosyan G, Pickren JW, Cabrera A. Melanosis of the esophagus. Cancer. 1963;16:48–50.
Odze RD, Goldblum JR. Odze and Goldblum surgical pathology of the GI tract, liver, biliary tract, and pancreas. Philadelphia: Elsevier - Health Sciences Division; 2014.
Crespi M, Munoz N, Grassi A, Qiong S, Jing WK, Jien LJ. Precursor lesions of oesophageal cancer in a low-risk population in China: comparison with high-risk populations. Int J Cancer. 1984;34(5):599–602.
Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, et al. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer. 1994;74(6):1686–92.
Lopes AB, Fagundes RB. Esophageal squamous cell carcinoma - precursor lesions and early diagnosis. World J Gastrointest Endosc. 2012;4(1):9–16.
Mandard AM, Marnay J, Gignoux M, Segol P, Blanc L, Ollivier JM, et al. Cancer of the esophagus and associated lesions: detailed pathologic study of 100 esophagectomy specimens. Hum Pathol. 1984;15(7):660–9.
Shimizu Y, Yoshida T, Kato M, Hirota J, Ono S, Nakagawa M, et al. Low-grade dysplasia component in early invasive squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2010;25(2):314–8.
Wang GQ, Abnet CC, Shen Q, Lewin KJ, Sun XD, Roth MJ, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54(2):187–92.
Takahashi H, Arimura Y, Masao H, Okahara S, Tanuma T, Kodaira J, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc. 2010;72(2):255–64. 64 e1–2.
Hashimoto CL, Iriya K, Baba ER, Navarro-Rodriguez T, Zerbini MC, Eisig JN, et al. Lugol’s dye spray chromoendoscopy establishes early diagnosis of esophageal cancer in patients with primary head and neck cancer. Am J Gastroenterol. 2005;100(2):275–82.
Takenaka R, Kawahara Y, Okada H, Hori K, Inoue M, Kawano S, et al. Narrow-band imaging provides reliable screening for esophageal malignancy in patients with head and neck cancers. Am J Gastroenterol. 2009;104(12):2942–8.
Tajima Y, Nakanishi Y, Tachimori Y, Kato H, Watanabe H, Yamaguchi H, et al. Significance of involvement by squamous cell carcinoma of the ducts of esophageal submucosal glands. Analysis of 201 surgically resected superficial squamous cell carcinomas. Cancer. 2000;89(2):248–54.
Abraham SC, Wang H, Wang KK, Wu TT. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma. Am J Surg Pathol. 2008;32(7):1068–74.
Wang WC, Wu TT, Chandan VS, Lohse CM, Zhang L. Ki-67 and ProExC are useful immunohistochemical markers in esophageal squamous intraepithelial neoplasia. Hum Pathol. 2011;42(10):1430–7.
Richter JE. Surgery for reflux disease: reflections of a gastroenterologist. N Engl J Med. 1992;326(12):825–7.
Wild CP, Hardie LJ. Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 2003;3(9):676–84.
Westhoff B, Brotze S, Weston A, McElhinney C, Cherian R, Mayo MS, et al. The frequency of Barrett’s esophagus in high-risk patients with chronic GERD. Gastrointest Endosc. 2005;61(2):226–31.
Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123(2):461–7.
Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin N Am. 1997;26(3):487–94.
Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211.
Kamat P, Wen S, Morris J, Anandasabapathy S. Exploring the association between elevated body mass index and Barrett’s esophagus: a systematic review and meta-analysis. Ann Thorac Surg. 2009;87(2):655–62.
Wang KK, Sampliner RE, Practice Parameters Committee of the American College of G. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103(3):788–97.
Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998;93(7):1028–32.
Riddell RH. The biopsy diagnosis of gastroesophageal reflux disease, “carditis,” and Barrett’s esophagus, and sequelae of therapy. Am J Surg Pathol. 1996;20(Suppl 1):S31–50.
Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127(1):310–30.
Odze RD. Unraveling the mystery of the gastroesophageal junction: a pathologist’s perspective. Am J Gastroenterol. 2005;100(8):1853–67.
Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus. Gut. 2006;55(4):442.
Ogiya K, Kawano T, Ito E, Nakajima Y, Kawada K, Nishikage T, et al. Lower esophageal palisade vessels and the definition of Barrett’s esophagus. Dis Esophagus. 2008;21(7):645–9.
Gatenby PA, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol. 2008;43(5):524–30.
Kelty CJ, Gough MD, Van Wyk Q, Stephenson TJ, Ackroyd R. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol. 2007;42(11):1271–4.
Glickman JN, Wang H, Das KM, Goyal RK, Spechler SJ, Antonioli D, et al. Phenotype of Barrett’s esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol. 2001;25(1):87–94.
Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, Ravelli P, et al. Risk factors for Barrett’s esophagus: a case-control study. Int J Cancer. 2002;97(2):225–9.
Ofman JJ, Shaheen NJ, Desai AA, Moody B, Bozymski EM, Weinstein WM. The quality of care in Barrett’s esophagus: endoscopist and pathologist practices. Am J Gastroenterol. 2001;96(3):876–81.
Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett’s oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut. 1992;33(9):1155–8.
Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, et al. Predictors for neoplastic progression in patients with Barrett’s Esophagus: a prospective cohort study. Am J Gastroenterol. 2011;106(7):1231–8.
Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol. 2002;97(8):1930–6.
Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med. 2000;132(8):612–20.
Hornick JL, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, et al. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett’s esophagus. Am J Surg Pathol. 2005;29(3):372–80.
Mino-Kenudson M, Ban S, Ohana M, Puricelli W, Deshpande V, Shimizu M, et al. Buried dysplasia and early adenocarcinoma arising in Barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol. 2007;31(3):403–9.
Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–88.
Weinstein WM, Ippoliti AF. The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest Endosc. 1996;44(1):91–5.
Srivastava A, Odze RD, Lauwers GY, Redston M, Antonioli DA, Glickman JN. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. Am J Surg Pathol. 2007;31(11):1733–41.
Antonioli DA, Wang HH. Morphology of Barrett’s esophagus and Barrett’s-associated dysplasia and adenocarcinoma. Gastroenterol Clin N Am. 1997;26(3):495–506.
Odze RD. Diagnosis and grading of dysplasia in Barrett’s oesophagus. J Clin Pathol. 2006;59(10):1029–38.
Wang HH, Zeroogian JM, Spechler SJ, Goyal RK, Antonioli DA. Prevalence and significance of pancreatic acinar metaplasia at the gastroesophageal junction. Am J Surg Pathol. 1996;20(12):1507–10.
Chen YY, Wang HH, Antonioli DA, Spechler SJ, Zeroogian JM, Goyal R, et al. Significance of acid-mucin-positive nongoblet columnar cells in the distal esophagus and gastroesophageal junction. Hum Pathol. 1999;30(12):1488–95.
Shields HM, Rosenberg SJ, Zwas FR, Ransil BJ, Lembo AJ, Odze R. Prospective evaluation of multilayered epithelium in Barrett’s esophagus. Am J Gastroenterol. 2001;96(12):3268–73.
Hahn HP, Shahsafaei A, Odze RD. Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett esophagus. Am J Surg Pathol. 2008;32(10):1454–61.
Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol. 1988;19(2):166–78.
Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47(2):251–5.
Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett’s esophagus cohort. Am J Surg Pathol. 2006;30(4):423–35.
Brown IS, Whiteman DC, Lauwers GY. Foveolar type dysplasia in Barrett esophagus. Mod Pathol. 2010;23(6):834–43.
Souza RF, Morales CP, Spechler SJ. Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett’s oesophagus. Aliment Pharmacol Ther. 2001;15(8):1087–100.
Hornick JL, Odze RD. Neoplastic precursor lesions in Barrett’s esophagus. Gastroenterol Clin N Am. 2007;36(4):775–96. v.
Thurberg BL, Duray PH, Odze RD. Polypoid dysplasia in Barrett’s esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases. Hum Pathol. 1999;30(7):745–52.
Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120(7):1630–9.
Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000;95(11):3089–96.
Asthana N, Mandich D, Ligato S. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett’s esophagus. Am J Surg Pathol. 2008;32(10):1581–5.
Montgomery E, Bronner MP, Greenson JK, Haber MM, Hart J, Lamps LW, et al. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up. Am J Gastroenterol. 2002;97(1):27–31.
Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32(4):368–78.
Zhang X, Huang Q, Goyal RK, Odze RD. DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett’s esophagus and associated neoplastic lesions. Am J Surg Pathol. 2008;32(9):1327–35.
Rucker-Schmidt RL, Sanchez CA, Blount PL, Ayub K, Li X, Rabinovitch PS, et al. Nonadenomatous dysplasia in Barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol. 2009;33(6):886–93.
Mahajan D, Bennett AE, Liu X, Bena J, Bronner MP. Grading of gastric foveolar-type dysplasia in Barrett’s esophagus. Mod Pathol. 2010;23(1):1–11.
Naini BV, Souza RF, Odze RD. Barrett’s esophagus: a comprehensive and contemporary review for pathologists. Am J Surg Pathol. 2016;40(5):e45–66.
Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101(5):855–9.
Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010. p. 417.
Ina H, Shibuya H, Ohashi I, Kitagawa M. The frequency of a concomitant early esophageal cancer in male patients with oral and oropharyngeal cancer. Screening results using Lugol dye endoscopy. Cancer. 1994;73(8):2038–41.
Takubo K, Aida J, Sawabe M, Kurosumi M, Arima M, Fujishiro M, et al. Early squamous cell carcinoma of the oesophagus: the Japanese viewpoint. Histopathology. 2007;51(6):733–42.
Lin DC, Du XL, Wang MR. Protein alterations in ESCC and clinical implications: a review. Dis Esophagus. 2009;22(1):9–20.
Lu YK, Li YM, Gu YZ. Cancer of esophagus and esophagogastric junction: analysis of results of 1,025 resections after 5 to 20 years. Ann Thorac Surg. 1987;43(2):176–81.
Ide H, Nakamura T, Hayashi K, Endo T, Kobayashi A, Eguchi R, et al. Esophageal squamous cell carcinoma: pathology and prognosis. World J Surg. 1994;18(3):321–30.
Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. Incidence and prognostic significance of vascular and neural invasion in squamous cell carcinomas of the esophagus. Int J Cancer. 1995;61(3):333–6.
Sarbia M, Bittinger F, Porschen R, Dutkowski P, Willers R, Gabbert HE. Prognostic value of histopathologic parameters of esophageal squamous cell carcinoma. Cancer. 1995;76(6):922–7.
Amin MB, Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. Switzerland: Springer; 2017. p. xvii. 1024 pages.
Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133(1):24–31.
Mori M, Matsuda H, Kuwano H, Matsuura H, Sugimachi K. Oesophageal squamous cell carcinoma with lymphoid stroma. A case report. Virchows Arch A Pathol Anat Histopathol. 1989;415(5):473–9.
Takubo K, Takai A, Takayama S, Sasajima K, Yamashita K, Fujita K. Intraductal spread of esophageal squamous cell carcinoma. Cancer. 1987;59(10):1751–7.
Tsang WY, Chan JK, Lee KC, Leung AK, Fu YT. Basaloid-squamous carcinoma of the upper aerodigestive tract and so-called adenoid cystic carcinoma of the oesophagus: the same tumour type? Histopathology. 1991;19(1):35–46.
Kobayashi Y, Nakanishi Y, Taniguchi H, Sekine S, Igaki H, Tachimori Y, et al. Histological diversity in basaloid squamous cell carcinoma of the esophagus. Dis Esophagus. 2009;22(3):231–8.
Osborn NK, Keate RF, Trastek VF, Nguyen CC. Verrucous carcinoma of the esophagus: clinicopathophysiologic features and treatment of a rare entity. Dig Dis Sci. 2003;48(3):465–74.
Lauwers GY, Grant LD, Scott GV, Carr NJ, Sobin LH. Spindle cell squamous carcinoma of the esophagus: analysis of ploidy and tumor proliferative activity in a series of 13 cases. Hum Pathol. 1998;29(8):863–8.
Hanada M, Nakano K, Ii Y, Yamashita H. Carcinosarcoma of the esophagus with osseous and cartilagenous production. A combined study of keratin immunohistochemistry and electron microscopy. Acta Pathol Jpn. 1984;34(3):669–78.
Boone J, van Hillegersberg R, Offerhaus GJ, van Diest PJ, Borel Rinkes IH, Ten Kate FJ. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus. 2009;22(6):496–504.
Sawada G, Niida A, Hirata H, Komatsu H, Uchi R, Shimamura T, et al. An integrative analysis to identify driver genes in esophageal squamous cell carcinoma. PLoS One. 2015;10(10):e0139808.
Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer. 1996;69(3):225–35.
Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130(11):883–90.
Gatenby PA, Caygill CP, Ramus JR, Charlett A, Fitzgerald RC, Watson A. Short segment columnar-lined oesophagus: an underestimated cancer risk? A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. Eur J Gastroenterol Hepatol. 2007;19(11):969–75.
Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000;133(3):165–75.
Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–6.
Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002;99(6):860–8.
Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology. 2002;122(3):633–40.
Smith RR, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients. Am J Surg Pathol. 1984;8(8):563–73.
Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett’s esophagus. Am J Clin Pathol. 1987;87(3):301–12.
Chejfec G, Jablokow VR, Gould VE. Linitis plastica carcinoma of the esophagus. Cancer. 1983;51(11):2139–43.
Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87(2):392–8. discussion 8-9.
Hornick JL, Farraye FA, Odze RD. Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett’s-associated adenocarcinoma. Am J Surg Pathol. 2006;30(1):28–35.
Torres C, Turner JR, Wang HH, Richards W, Sugarbaker D, Shahsafaei A, et al. Pathologic prognostic factors in Barrett’s associated adenocarcinoma: a follow-up study of 96 patients. Cancer. 1999;85(3):520–8.
Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.
Hamilton K, Chiappori A, Olson S, Sawyers J, Johnson D, Washington K. Prevalence and prognostic significance of neuroendocrine cells in esophageal adenocarcinoma. Mod Pathol. 2000;13(5):475–81.
Yachida S, Nakanishi Y, Shimoda T, Nimura S, Igaki H, Tachimori Y, et al. Adenosquamous carcinoma of the esophagus. Clinicopathologic study of 18 cases. Oncology. 2004;66(3):218–25.
Gowryshankar A, Nagaraja V, Eslick GD. HER2 status in Barrett’s esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol. 2014;5(1):25–35.
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345–63.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805.
Ajani JA, Bentrem DJ, Besh S, D’Amico TA, Das P, Denlinger C, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 2013;11(5):531–46.
Bell-Thomson J, Haggitt RC, Ellis FH Jr. Mucoepidermoid and adenoid cystic carcinomas of the esophagus. J Thorac Cardiovasc Surg. 1980;79(3):438–46.
Woodard BH, Shelburne JD, Vollmer RT, Postlethwait RW. Mucoepidermoid carcinoma of the esophagus: a case report. Hum Pathol. 1978;9(3):352–4.
Sasajima K, Watanabe M, Takubo K, Takai A, Yamashita K, Onda M. Mucoepidermoid carcinoma of the esophagus: report of two cases and review of the literature. Endoscopy. 1990;22(3):140–3.
Akagi I, Miyashita M, Makino H, Nomura T, Ohkawa K, Tajiri T. Basaloid squamous cell carcinoma of the esophagus: report of two cases. J Nippon Med Sch. 2008;75(6):354–60.
Kabuto T, Taniguchi K, Iwanaga T, Terasawa T, Sano M, Tateishi R, et al. Primary adenoid cystic carcinoma of the esophagus: report of a case. Cancer. 1979;43(6):2452–6.
Hoda SA, Hajdu SI. Small cell carcinoma of the esophagus. Cytology and immunohistology in four cases. Acta Cytol. 1992;36(2):113–20.
Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg. 2005;29(1):92–101.
Takubo K, Nakamura K, Sawabe M, Arai T, Esaki Y, Miyashita M, et al. Primary undifferentiated small cell carcinoma of the esophagus. Hum Pathol. 1999;30(2):216–21.
Cary NR, Barron DJ, McGoldrick JP, Wells FC. Combined oesophageal adenocarcinoma and carcinoid in Barrett’s oesophagitis: potential role of enterochromaffin-like cells in oesophageal malignancy. Thorax. 1993;48(4):404–5.
Chong FK, Graham JH, Madoff IM. Mucin-producing carcinoid (“composite tumor”) of upper third of esophagus: a variant of carcinoid tumor. Cancer. 1979;44(5):1853–9.
Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32(9):1404–11.
Siegal A, Swartz A. Malignant carcinoid of oesophagus. Histopathology. 1986;10(7):761–5.
Nawroz IM. Malignant carcinoid tumour of oesophagus. Histopathology. 1987;11(8):879–80.
Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(Suppl 1):S9–27.
Chuah SK, Hu TH, Kuo CM, Chiu KW, Kuo CH, Wu KL, et al. Upper gastrointestinal carcinoid tumors incidentally found by endoscopic examinations. World J Gastroenterol. 2005;11(44):7028–32.
Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79(4):813–29.
Yun JP, Zhang MF, Hou JH, Tian QH, Fu J, Liang XM, et al. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 cases. BMC Cancer. 2007;7:38.
Lu J, Xue LY, Lu N, Zou SM, Liu XY, Wen P. Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases. Dis Esophagus. 2010;23(2):153–9.
Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6):529–53.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.
Briggs JC, Ibrahim NB. Oat cell carcinomas of the oesophagus: a clinico-pathological study of 23 cases. Histopathology. 1983;7(2):261–77.
Ho KJ, Herrera GA, Jones JM, Alexander CB. Small cell carcinoma of the esophagus: evidence for a unified histogenesis. Hum Pathol. 1984;15(5):460–8.
Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554–60.
Ito H, Hata J, Yokozaki H, Nakatani H, Oda N, Tahara E. Tubular adenoma of the human stomach. An immunohistochemical analysis of gut hormones, serotonin, carcinoembryonic antigen, secretory component, and lysozyme. Cancer. 1986;58(10):2264–72.
Oberhuber G, Stolte M. Gastric polyps: an update of their pathology and biological significance. Virchows Arch. 2000;437(6):581–90.
Domizio P, Talbot IC, Spigelman AD, Williams CB, Phillips RK. Upper gastrointestinal pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. J Clin Pathol. 1990;43(9):738–43.
Nakamura T, Nakano G. Histopathological classification and malignant change in gastric polyps. J Clin Pathol. 1985;38(7):754–64.
Abraham SC, Park SJ, Lee JH, Mugartegui L, Wu TT. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod Pathol. 2003;16(8):786–95.
Ito H, Yasui W, Yoshida K, Nakayama H, Tahara E. Depressed tubular adenoma of the stomach: pathological and immunohistochemical features. Histopathology. 1990;17(5):419–26.
Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut. 1999;45(5):784–90.
Tosi P, Baak JP, Luzi P, Miracco C, Lio R, Barbini P. Morphometric distinction of low- and high-grade dysplasias in gastric biopsies. Hum Pathol. 1989;20(9):839–44.
Lansdown M, Quirke P, Dixon MF, Axon AT, Johnston D. High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut. 1990;31(9):977–83.
Vieth M, Kushima R, Borchard F, Stolte M. Pyloric gland adenoma: a clinico-pathological analysis of 90 cases. Virchows Arch. 2003;442(4):317–21.
Chen ZM, Scudiere JR, Abraham SC, Montgomery E. Pyloric gland adenoma: an entity distinct from gastric foveolar type adenoma. Am J Surg Pathol. 2009;33(2):186–93.
Stewart BW, Wild CP. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014.
Locke GR 3rd, Talley NJ, Carpenter HA, Harmsen WS, Zinsmeister AR, Melton LJ 3rd. Changes in the site- and histology-specific incidence of gastric cancer during a 50-year period. Gastroenterology. 1995;109(6):1750–6.
Kuipers EJ. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther. 1997;11(Suppl 1):71–88.
Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128(7):765–70.
Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology. 1995;109(5):1541–6.
Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg. 1999;86(4):529–35.
Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457–9.
Allum WH, Powell DJ, McConkey CC, Fielding JW. Gastric cancer: a 25-year review. Br J Surg. 1989;76(6):535–40.
Capella C, Frigerio B, Cornaggia M, Solcia E, Pinzon-Trujillo Y, Chejfec G. Gastric parietal cell carcinoma--a newly recognized entity: light microscopic and ultrastructural features. Histopathology. 1984;8(5):813–24.
Bonar SF, Sweeney EC. The prevalence, prognostic significance and hormonal content of endocrine cells in gastric cancer. Histopathology. 1986;10(1):53–63.
Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34(5):609–19.
Singhi AD, Lazenby AJ, Montgomery EA. Gastric adenocarcinoma with chief cell differentiation: a proposal for reclassification as oxyntic gland polyp/adenoma. Am J Surg Pathol. 2012;36(7):1030–5.
Ooi A, Nakanishi I, Itoh T, Ueda H, Mai M. Predominant Paneth cell differentiation in an intestinal type gastric cancer. Pathol Res Pract. 1991;187(2–3):220–5.
Fiocca R, Villani L, Tenti P, Solcia E, Cornaggia M, Frigerio B, et al. Characterization of four main cell types in gastric cancer: foveolar, mucopeptic, intestinal columnar and goblet cells. An histopathologic, histochemical and ultrastructural study of “early” and “advanced” tumours. Pathol Res Pract. 1987;182(3):308–25.
Setala LP, Kosma VM, Marin S, Lipponen PK, Eskelinen MJ, Syrjanen KJ, et al. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer. 1996;74(5):766–72.
Tanaka A, Watanabe T, Okuno K, Yasutomi M. Perineural invasion as a predictor of recurrence of gastric cancer. Cancer. 1994;73(3):550–5.
Ming SC. Gastric carcinoma. A pathobiological classification. Cancer. 1977;39(6):2475–85.
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
Roy P, Piard F, Dusserre-Guion L, Martin L, Michiels-Marzais D, Faivre J. Prognostic comparison of the pathological classifications of gastric cancer: a population-based study. Histopathology. 1998;33(4):304–10.
Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. World J Gastroenterol. 2014;20(19):5679–84.
Mori M, Sakaguchi H, Akazawa K, Tsuneyoshi M, Sueishi K, Sugimachi K. Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma. Hum Pathol. 1995;26(5):504–8.
Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203(2):681–7.
Fiocca R, Villani L, Tenti P, Cornaggia M, Finzi G, Riva C, et al. The foveolar cell component of gastric cancer. Hum Pathol. 1990;21(3):260–70.
Machado JC, Nogueira AM, Carneiro F, Reis CA, Sobrinho-Simoes M. Gastric carcinoma exhibits distinct types of cell differentiation: an immunohistochemical study of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, MUC5AC, and MUC6). J Pathol. 2000;190(4):437–43.
Oda K, Tamaru J, Takenouchi T, Mikata A, Nunomura M, Saitoh N, et al. Association of Epstein-Barr virus with gastric carcinoma with lymphoid stroma. Am J Pathol. 1993;143(4):1063–71.
Matsunou H, Konishi F, Hori H, Ikeda T, Sasaki K, Hirose Y, et al. Characteristics of Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma in Japan. Cancer. 1996;77(10):1998–2004.
Minamoto T, Mai M, Watanabe K, Ooi A, Kitamura T, Takahashi Y, et al. Medullary carcinoma with lymphocytic infiltration of the stomach. Clinicopathologic study of 27 cases and immunohistochemical analysis of the subpopulations of infiltrating lymphocytes in the tumor. Cancer. 1990;66(5):945–52.
Nakamura S, Ueki T, Yao T, Ueyama T, Tsuneyoshi M. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. Cancer. 1994;73(9):2239–49.
dos Santos NR, Seruca R, Constancia M, Seixas M, Sobrinho-Simoes M. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology. 1996;110(1):38–44.
Hisamichi S. Screening for gastric cancer. World J Surg. 1989;13(1):31–7.
Marubashi S, Yano H, Monden T, Tateishi H, Kanoh T, Iwazawa T, et al. Primary squamous cell carcinoma of the stomach. Gastric Cancer. 1999;2(2):136–41.
Mori M, Iwashita A, Enjoji M. Adenosquamous carcinoma of the stomach. A clinicopathologic analysis of 28 cases. Cancer. 1986;57(2):333–9.
Yoshida K, Manabe T, Tsunoda T, Kimoto M, Tadaoka Y, Shimizu M. Early gastric cancer of adenosquamous carcinoma type: report of a case and review of literature. Jpn J Clin Oncol. 1996;26(4):252–7.
Robey-Cafferty SS, Grignon DJ, Ro JY, Cleary KR, Ayala AG, Ordonez NG, et al. Sarcomatoid carcinoma of the stomach. A report of three cases with immunohistochemical and ultrastructural observations. Cancer. 1990;65(7):1601–6.
Randjelovic T, Filipovic B, Babic D, Cemerikic V, Filipovic B. Carcinosarcoma of the stomach: a case report and review of the literature. World J Gastroenterol. 2007;13(41):5533–6.
Ikeda Y, Kosugi S, Nishikura K, Ohashi M, Kanda T, Kobayashi T, et al. Gastric carcinosarcoma presenting as a huge epigastric mass. Gastric Cancer. 2007;10(1):63–8.
Dundas SA, Slater DN, Wagner BE, Mills PA. Gastric adenocarcinoleiomyosarcoma: a light, electron microscopic and immunohistological study. Histopathology. 1988;13(3):347–50.
Nakayama Y, Murayama H, Iwasaki H, Iwanaga S, Kikuchi M, Ikeda S, et al. Gastric carcinosarcoma (sarcomatoid carcinoma) with rhabdomyoblastic and osteoblastic differentiation. Pathol Int. 1997;47(8):557–63.
Yamazaki K. A gastric carcinosarcoma with neuroendocrine cell differentiation and undifferentiated spindle-shaped sarcoma component possibly progressing from the conventional tubular adenocarcinoma; an immunohistochemical and ultrastructural study. Virchows Arch. 2003;442(1):77–81.
Sato Y, Shimozono T, Kawano S, Toyoda K, Onoe K, Asada Y, et al. Gastric carcinosarcoma, coexistence of adenosquamous carcinoma and rhabdomyosarcoma: a case report. Histopathology. 2001;39(5):543–4.
Kallakury BV, Bui HX, del Rosario A, Wallace J, Solis OG, Ross JS. Primary gastric adenosarcoma. Arch Pathol Lab Med. 1993;117(3):299–301.
Inagawa S, Shimazaki J, Hori M, Yoshimi F, Adachi S, Kawamoto T, et al. Hepatoid adenocarcinoma of the stomach. Gastric Cancer. 2001;4(1):43–52.
Yamazawa S, Ushiku T, Shinozaki-Ushiku A, Hayashi A, Iwasaki A, Abe H, et al. Gastric cancer with primitive enterocyte phenotype: an aggressive subgroup of intestinal-type adenocarcinoma. Am J Surg Pathol. 2017;41(7):989–97.
Liu X, Cheng Y, Sheng W, Lu H, Xu X, Xu Y, et al. Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach. Am J Surg Pathol. 2010;34(10):1465–71.
Ishikura H, Kirimoto K, Shamoto M, Miyamoto Y, Yamagiwa H, Itoh T, et al. Hepatoid adenocarcinomas of the stomach. An analysis of seven cases. Cancer. 1986;58(1):119–26.
Motoyama T, Aizawa K, Watanabe H, Fukase M, Saito K. Alpha-fetoprotein producing gastric carcinomas: a comparative study of three different subtypes. Acta Pathol Jpn. 1993;43(11):654–61.
Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer. 1998;1(1):31–50.
Petrella T, Montagnon J, Roignot P, Van Nieuvanhuyse A, Matagrin C, Michiels-Marzais D, et al. Alphafetoprotein-producing gastric adenocarcinoma. Histopathology. 1995;26(2):171–5.
Byrne D, Holley MP, Cuschieri A. Parietal cell carcinoma of the stomach: association with long-term survival after curative resection. Br J Cancer. 1988;58(1):85–7.
Hayashi I, Muto Y, Fujii Y, Morimatsu M. Mucoepidermoid carcinoma of the stomach. J Surg Oncol. 1987;34(2):94–9.
Amrikachi M, Ro JY, Ordonez NG, Ayala AG. Adenocarcinomas of the gastrointestinal tract with prominent rhabdoid features. Ann Diagn Pathol. 2002;6(6):357–63.
Oda, Kondo H, Yamao T, Saito D, Ono H, Gotoda T, et al. Metastatic tumors to the stomach: analysis of 54 patients diagnosed at endoscopy and 347 autopsy cases. Endoscopy. 2001;33(6):507–10.
Kim GH, Ahn JY, Jung HY, Park YS, Kim MJ, Choi KD, et al. Clinical and endoscopic features of metastatic tumors in the stomach. Gut Liver. 2015;9(5):615–22.
Yang Y, Lu S, Zeng W, Xie S, Xiao S. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors. Ann Diagn Pathol. 2017;26:1–5.
O’Connell FP, Wang HH, Odze RD. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med. 2005;129(3):338–47.
Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004;122(1):61–9.
Patel DS, Khandeparkar SGS, Joshi AR, Kulkarni MM, Dhande B, Lengare P, et al. Immunohistochemical Study of MUC1, MUC2 and MUC5AC expression in primary breast carcinoma. J Clin Diagn Res. 2017;11(4):EC30–EC4.
Brito MJ, Williams GT, Thompson H, Filipe MI. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut. 1994;35(12):1697–700.
Milne AN, Carvalho R, Morsink FM, Musler AR, de Leng WW, Ristimaki A, et al. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol. 2006;19(4):564–72.
Lee JH, Abraham SC, Kim HS, Nam JH, Choi C, Lee MC, et al. Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am J Pathol. 2002;161(2):611–8.
Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, et al. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci U S A. 1994;91(19):8772–6.
Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Investig. 1998;78(9):1143–53.
Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, et al. A novel germ line juxtamembrane met mutation in human gastric cancer. Oncogene. 2000;19(43):4947–53.
Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17(1):1–12.
Jardim DL, de Melo GD, Falchook GS, Janku F, Zinner R, Wheler JJ, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014;5(7):1837–45.
Metzger ML, Behrens HM, Boger C, Haag J, Kruger S, Rocken C. MET in gastric cancer--discarding a 10% cutoff rule. Histopathology. 2016;68(2):241–53.
Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 2013;26(12):1632–41.
Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012;107(2):325–33.
Yildiz Y, Sokmensuer C, Yalcin S. Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors. Onco Targets Ther. 2016;9:5809–17.
Wu MS, Lee CW, Shun CT, Wang HP, Lee WJ, Chang MC, et al. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer. 2000;27(4):403–11.
Chung DC, Yoon SS, Lauwers GY, Patel D. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med. 2007;357(3):283–91.
Pedrazzani C, Corso G, Marrelli D, Roviello F. E-cadherin and hereditary diffuse gastric cancer. Surgery. 2007;142(5):645–57.
Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36(12):873–80.
Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4(3):262–75.
Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155(2):337–42.
Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344(25):1904–9.
Rogers WM, Dobo E, Norton JA, Van Dam J, Jeffrey RB, Huntsman DG, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol. 2008;32(6):799–809.
Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Jarvinen HJ. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer. 1997;74(5):551–5.
Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol. 2000;157(3):747–54.
Hofgartner WT, Thorp M, Ramus MW, Delorefice G, Chey WY, Ryan CK, et al. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol. 1999;94(8):2275–81.
Zwick A, Munir M, Ryan CK, Gian J, Burt RW, Leppert M, et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology. 1997;113(2):659–63.
Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–56.
Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145(3):554–65.
Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, et al. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016;29(7):772–84.
Liu Z, Mira JL, Cruz-Caudillo JC. Primary gastric choriocarcinoma: a case report and review of the literature. Arch Pathol Lab Med. 2001;125(12):1601–4.
Imai Y, Kawabe T, Takahashi M, Matsumura M, Komatsu Y, Hamada E, et al. A case of primary gastric choriocarcinoma and a review of the Japanese literature. J Gastroenterol. 1994;29(5):642–6.
Namikawa T, Kobayashi M, Okabayashi T, Ozaki S, Nakamura S, Yamashita K, et al. Primary gastric small cell carcinoma: report of a case and review of the literature. Med Mol Morphol. 2005;38(4):256–61.
Matsui K, Jin XM, Kitagawa M, Miwa A. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants. Arch Pathol Lab Med. 1998;122(11):1010–7.
Kusayanagi S, Konishi K, Miyasaka N, Sasaki K, Kurahashi T, Kaneko K, et al. Primary small cell carcinoma of the stomach. J Gastroenterol Hepatol. 2003;18(6):743–7.
Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717–51.
Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651–68.
La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42(10):1373–84.
Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168–72.
Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer. 1994;73(8):2053–8.
Borch K, Renvall H, Kullman E, Wilander E. Gastric carcinoid associated with the syndrome of hypergastrinemic atrophic gastritis. A prospective analysis of 11 cases. Am J Surg Pathol. 1987;11(6):435–44.
Solcia E, Capella C, Fiocca R, Rindi G, Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol. 1990;14(6):503–13.
Ooi A, Ota M, Katsuda S, Nakanishi I, Sugawara H, Takahashi I. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocr Pathol. 1995;6(3):229–37.
Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology. 1999;116(3):532–42.
Carney JA, Go VL, Fairbanks VF, Moore SB, Alport EC, Nora FE. The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Intern Med. 1983;99(6):761–6.
Muller J, Kirchner T, Muller-Hermelink HK. Gastric endocrine cell hyperplasia and carcinoid tumors in atrophic gastritis type A. Am J Surg Pathol. 1987;11(12):909–17.
Pandol SJ. The exocrine pancreas. Colloquium series on integrated systems physiology: from molecule to function to disease. San Rafael: Morgan & Claypool Life Sciences; 2010.
Stelow EB, Adams RB, Moskaluk CA. The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms. Am J Surg Pathol. 2006;30(1):36–41.
Brockie E, Anand A, Albores-Saavedra J. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma. Ann Diagn Pathol. 1998;2(5):286–92.
Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol. 1998;22(2):163–9.
Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, et al. A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol. 2015;39(12):1730–41.
Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977–87.
Chen J, Baithun SI. Morphological study of 391 cases of exocrine pancreatic tumours with special reference to the classification of exocrine pancreatic carcinoma. J Pathol. 1985;146(1):17–29.
Adsay V, Logani S, Sarkar F, Crissman J, Vaitkevicius V. Foamy gland pattern of pancreatic ductal adenocarcinoma: a deceptively benign-appearing variant. Am J Surg Pathol. 2000;24(4):493–504.
Bagci P, Andea AA, Basturk O, Jang KT, Erbarut I, Adsay V. Large duct type invasive adenocarcinoma of the pancreas with microcystic and papillary patterns: a potential microscopic mimic of non-invasive ductal neoplasia. Mod Pathol. 2012;25(3):439–48.
Dursun N, Feng J, Basturk O, Bandyopadhyay S, Cheng JD, Adsay VN. Vacuolated cell pattern of pancreatobiliary adenocarcinoma: a clinicopathological analysis of 24 cases of a poorly recognized distinctive morphologic variant important in the differential diagnosis. Virchows Arch. 2010;457(6):643–9.
Zerbi A, De Nardi P, Braga M, Radice F, Sironi M, Di Carlo V. An oncocytic carcinoma of the pancreas with pulmonary and subcutaneous metastases. Pancreas. 1993;8(1):116–9.
Bandyopadhyay S, Basturk O, Coban I, Thirabanjasak D, Liang H, Altinel D, et al. Isolated solitary ducts (naked ducts) in adipose tissue: a specific but underappreciated finding of pancreatic adenocarcinoma and one of the potential reasons of understaging and high recurrence rate. Am J Surg Pathol. 2009;33(3):425–9.
Luttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Kloppel G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000;191(2):154–61.
Adsay NV, Basturk O, Bonnett M, Kilinc N, Andea AA, Feng J, et al. A proposal for a new and more practical grading scheme for pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2005;29(6):724–33.
Giulianotti PC, Boggi U, Fornaciari G, Bruno J, Rossi G, Giardino D, et al. Prognostic value of histological grading in ductal adenocarcinoma of the pancreas. Kloppel vs TNM grading. Int J Pancreatol. 1995;17(3):279–89.
Duval JV, Savas L, Banner BF. Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med. 2000;124(8):1196–200.
Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16(5):403–10.
Luttges J, Zamboni G, Longnecker D, Kloppel G. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol. 2001;25(7):942–8.
Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res. 2001;7(12):4033–40.
Monges GM, Mathoulin-Portier MP, Acres RB, Houvenaeghel GF, Giovannini MF, Seitz JF, et al. Differential MUC 1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples. Am J Clin Pathol. 1999;112(5):635–40.
Moy AP, Arora K, Deshpande V. Albumin expression distinguishes bile duct adenomas from metastatic adenocarcinoma. Histopathology. 2016;69(3):423–30.
Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol. 2000;156(1):37–43.
Tascilar M, Offerhaus GJ, Altink R, Argani P, Sohn TA, Yeo CJ, et al. Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Am J Clin Pathol. 2001;116(6):831–7.
Adsay NV, Pierson C, Sarkar F, Abrams J, Weaver D, Conlon KC, et al. Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol. 2001;25(1):26–42.
Seidel G, Zahurak M, Iacobuzio-Donahue C, Sohn TA, Adsay NV, Yeo CJ, et al. Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. Am J Surg Pathol. 2002;26(1):56–63.
Kardon DE, Thompson LD, Przygodzki RM, Heffess CS. Adenosquamous carcinoma of the pancreas: a clinicopathologic series of 25 cases. Mod Pathol. 2001;14(5):443–51.
Yamaguchi K, Enjoji M. Adenosquamous carcinoma of the pancreas: a clinicopathologic study. J Surg Oncol. 1991;47(2):109–16.
Hruban RH, Pitman MB, Klimstra DS, American Registry of Pathology, Armed Forces Institute of Pathology (U.S.). Tumors of the pancreas. Washington, D.C.: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology; 2007. xviii, 422 p.
Paal E, Thompson LD, Frommelt RA, Przygodzki RM, Heffess CS. A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann Diagn Pathol. 2001;5(3):129–40.
Alguacil-Garcia A, Weiland LH. The histologic spectrum, prognosis, and histogenesis of the sarcomatoid carcinoma of the pancreas. Cancer. 1977;39(3):1181–9.
Dhall D, Klimstra DS. The cellular composition of osteoclastlike giant cell-containing tumors of the pancreatobiliary tree. Am J Surg Pathol. 2008;32(2):335–7. author response 7.
Dworak O, Wittekind C, Koerfgen HP, Gall FP. Osteoclastic giant cell tumor of the pancreas. An immunohistological study and review of the literature. Pathol Res Pract. 1993;189(2):228–31. discussion 32-4.
Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas. 2006;32(3):271–5.
Banville N, Geraghty R, Fox E, Leahy DT, Green A, Keegan D, et al. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol. 2006;37(11):1498–502.
Wilentz RE, Goggins M, Redston M, Marcus VA, Adsay NV, Sohn TA, et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol. 2000;156(5):1641–51.
Nakata B, Wang YQ, Yashiro M, Nishioka N, Tanaka H, Ohira M, et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res. 2002;8(8):2536–40.
Hruban RH, Molina JM, Reddy MN, Boitnott JK. A neoplasm with pancreatic and hepatocellular differentiation presenting with subcutaneous fat necrosis. Am J Clin Pathol. 1987;88(5):639–45.
Marchegiani G, Gareer H, Parisi A, Capelli P, Bassi C, Salvia R. Pancreatic hepatoid carcinoma: a review of the literature. Dig Surg. 2013;30(4–6):425–33.
Adsay NV, Klimstra DS, Compton CC. Cystic lesions of the pancreas. Introduction. Semin Diagn Pathol. 2000;17(1):1–6.
Albores-Saavedra J, Gould EW, Angeles-Angeles A, Henson DE. Cystic tumors of the pancreas. Pathol Annu. 1990;25(Pt 2):19–50.
Adsay NV, Klimstra DS. Cystic forms of typically solid pancreatic tumors. Semin Diagn Pathol. 2000;17(1):81–8.
Compton CC. Serous cystic tumors of the pancreas. Semin Diagn Pathol. 2000;17(1):43–55.
Egawa N, Maillet B, Klöppel G, Schröder S, Mukai K. Serous oligocystic and ill-demarcated adenoma of the pancreas: a variant of serous cystic adenoma. Virchows Arch. 1994;424(1):13–7.
Lewandrowski K, Warshaw A, Compton C. Macrocystic serous cystadenoma of the pancreas: a morphologic variant differing from microcystic adenoma. Hum Pathol. 1992;23(8):871–5.
Tseng JF, Warshaw AL, Sahani DV, Lauwers GY, Rattner DW, Fernandez-del CC. Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg. 2005;242(3):413–9. discussion 9-21.
King JC, Ng TT, White SC, Cortina G, Reber HA, Hines OJ. Pancreatic serous cystadenocarcinoma: a case report and review of the literature. J Gastrointest Surg. 2009;13(10):1864–8.
Bramis K, Petrou A, Papalambros A, Manzelli A, Mantonakis E, Brennan N, et al. Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. World J Surg Oncol. 2012;10:51.
Girelli R, Bassi C, Falconi M, De Santis L, Bonora A, Caldiron E, et al. Pancreatic cystic manifestations in von Hippel-Lindau disease. Int J Pancreatol. 1997;22(2):101–9.
Hough DM, Stephens DH, Johnson CD, Binkovitz LA. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol. 1994;162(5):1091–4.
Panarelli NC, Park KJ, Hruban RH, Klimstra DS. Microcystic serous cystadenoma of the pancreas with subtotal cystic degeneration: another neoplastic mimic of pancreatic pseudocyst. Am J Surg Pathol. 2012;36(5):726–31.
Thirabanjasak D, Basturk O, Altinel D, Cheng JD, Adsay NV. Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis? Pancreatology. 2009;9(1–2):182–8.
Perez-Ordonez B, Naseem A, Lieberman PH, Klimstra DS. Solid serous adenoma of the pancreas. The solid variant of serous cystadenoma? Am J Surg Pathol. 1996;20(11):1401–5.
Kosmahl M, Wagner J, Peters K, Sipos B, Kloppel G. Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J Surg Pathol. 2004;28(3):339–46.
Yasuhara Y, Sakaida N, Uemura Y, Senzaki H, Shikata N, Tsubura A. Serous microcystic adenoma (glycogen-rich cystadenoma) of the pancreas: study of 11 cases showing clinicopathological and immunohistochemical correlations. Pathol Int. 2002;52(4):307–12.
Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A. 2011;108(52):21188–93.
Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3(92):92ra66.
Moore PS, Zamboni G, Brighenti A, Lissandrini D, Antonello D, Capelli P, et al. Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q. Am J Pathol. 2001;158(1):317–21.
Thompson LD, Becker RC, Przygodzki RM, Adair CF, Heffess CS. Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J Surg Pathol. 1999;23(1):1–16.
Compagno J, Oertel JE. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol. 1978;69(6):573–80.
Wilentz RE, Albores-Saavedra J, Hruban RH. Mucinous cystic neoplasms of the pancreas. Semin Diagn Pathol. 2000;17(1):31–42.
Zamboni G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol. 1999;23(4):410–22.
Izumo A, Yamaguchi K, Eguchi T, Nishiyama K, Yamamoto H, Yonemasu H, et al. Mucinous cystic tumor of the pancreas: immunohistochemical assessment of “ovarian-type stroma”. Oncol Rep. 2003;10(3):515–25.
Hara T, Kawashima H, Ishigooka M, Kashiyama M, Takanashi S, Yamazaki S, et al. Mucinous cystic tumors of the pancreas. Surg Today. 2002;32(11):965–9.
Ridder GJ, Maschek H, Flemming P, Nashan B, Klempnauer J. Ovarian-like stroma in an invasive mucinous cystadenocarcinoma of the pancreas positive for inhibin. A hint concerning its possible histogenesis. Virchows Arch. 1998;432(5):451–4.
Hirano H, Morita K, Tachibana S, Okimura A, Fujisawa T, Ouchi S, et al. Undifferentiated carcinoma with osteoclast-like giant cells arising in a mucinous cystic neoplasm of the pancreas. Pathol Int. 2008;58(6):383–9.
Zamboni G, Terris B, Scarpa A, Kosmahl M, Capelli P, Klimstra DS, et al. Acinar cell cystadenoma of the pancreas: a new entity? Am J Surg Pathol. 2002;26(6):698–704.
Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 2002;26(4):466–71.
Yoshizawa K, Nagai H, Sakurai S, Hironaka M, Morinaga S, Saitoh K, et al. Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas. Virchows Arch. 2002;441(5):437–43.
Jimenez RE, Warshaw AL, Z’Graggen K, Hartwig W, Taylor DZ, Compton CC, et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg. 1999;230(4):501–9. discussion 9-11.
Adsay V, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, et al. Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: recommendations of verona consensus meeting. Ann Surg. 2016;263(1):162–77.
Matthaei H, Wu J, Dal Molin M, Shi C, Perner S, Kristiansen G, et al. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as “incipient IPMNs”. Am J Surg Pathol. 2014;38(3):360–3.
Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer. 2002;94(1):62–77.
Azar C, Van de Stadt J, Rickaert F, Deviere M, Baize M, Kloppel G, et al. Intraductal papillary mucinous tumours of the pancreas. Clinical and therapeutic issues in 32 patients. Gut. 1996;39(3):457–64.
Kloppel G. Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. Hepato-Gastroenterology. 1998;45(24):1981–5.
Loftus EV Jr, Olivares-Pakzad BA, Batts KP, Adkins MC, Stephens DH, Sarr MG, et al. Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic. Gastroenterology. 1996;110(6):1909–18.
Paal E, Thompson LD, Przygodzki RM, Bratthauer GL, Heffess CS. A clinicopathologic and immunohistochemical study of 22 intraductal papillary mucinous neoplasms of the pancreas, with a review of the literature. Mod Pathol. 1999;12(5):518–28.
Furukawa T, Kloppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447(5):794–9.
Adsay NV, Merati K, Andea A, Sarkar F, Hruban RH, Wilentz RE, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15(10):1087–95.
Adsay NV, Longnecker DS, Klimstra DS. Pancreatic tumors with cystic dilatation of the ducts: intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms. Semin Diagn Pathol. 2000;17(1):16–30.
Nakayama Y, Inoue H, Hamada Y, Takeshita M, Iwasaki H, Maeshiro K, et al. Intraductal tubular adenoma of the pancreas, pyloric gland type: a clinicopathologic and immunohistochemical study of 6 cases. Am J Surg Pathol. 2005;29(5):607–16.
Albores-Saavedra J, Sheahan K, O’Riain C, Shukla D. Intraductal tubular adenoma, pyloric type, of the pancreas: additional observations on a new type of pancreatic neoplasm. Am J Surg Pathol. 2004;28(2):233–8.
Kato N, Akiyama S, Motoyama T. Pyloric gland-type tubular adenoma superimposed on intraductal papillary mucinous tumor of the pancreas. Pyloric gland adenoma of the pancreas. Virchows Arch. 2002;440(2):205–8.
Bakotic BW, Robinson MJ, Sturm PD, Hruban RH, Offerhaus GJ, Albores-Saavedra J. Pyloric gland adenoma of the main pancreatic duct. Am J Surg Pathol. 1999;23(2):227–31.
Adsay NV, Merati K, Basturk O, Iacobuzio-Donahue C, Levi E, Cheng JD, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28(7):839–48.
Ishida M, Egawa S, Aoki T, Sakata N, Mikami Y, Motoi F, et al. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas. 2007;35(4):348–52.
Basturk O, Tan M, Bhanot U, Allen P, Adsay V, Scott SN, et al. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol. 2016;29(9):1058–69.
Schaberg KB, DiMaio MA, Longacre TA. Intraductal papillary mucinous neoplasms often contain epithelium from multiple subtypes and/or are unclassifiable. Am J Surg Pathol. 2016;40(1):44–50.
Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.
Terada T, Ohta T, Kitamura Y, Ashida K, Matsunaga Y. Cell proliferative activity in intraductal papillary-mucinous neoplasms and invasive ductal adenocarcinomas of the pancreas: an immunohistochemical study. Arch Pathol Lab Med. 1998;122(1):42–6.
Nagai E, Ueki T, Chijiiwa K, Tanaka M, Tsuneyoshi M. Intraductal papillary mucinous neoplasms of the pancreas associated with so-called “mucinous ductal ectasia”. Histochemical and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 1995;19(5):576–89.
Basturk O, Khayyata S, Klimstra DS, Hruban RH, Zamboni G, Coban I, et al. Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol. 2010;34(3):364–70.
Lee JH, Kim Y, Choi JW, Kim YS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springerplus. 2016;5(1):1172.
Satoh K, Shimosegawa T, Moriizumi S, Koizumi M, Toyota T. K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas. 1996;12(4):362–8.
Z’Graggen K, Rivera JA, Compton CC, Pins M, Werner J, Fernandez-del Castillo C, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg. 1997;226(4):491–8. discussion 8-500.
Chadwick B, Willmore-Payne C, Tripp S, Layfield LJ, Hirschowitz S, Holden J. Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas. Appl Immunohistochem Mol Morphol. 2009;17(1):31–9.
Biankin AV, Biankin SA, Kench JG, Morey AL, Lee CS, Head DR, et al. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut. 2002;50(6):861–8.
Sato N, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 2001;159(6):2017–22.
Tsai JH, Liau JY, Yuan CT, Cheng ML, Yuan RH, Jeng YM. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct. Histopathology. 2017;70(5):756–65.
Zauber P, Marotta S, Sabbath-Solitare M. GNAS mutations are associated with mucin production in low-grade appendiceal mucinous neoplasms, villous adenomas, and carcinomas. Hum Pathol. 2015;46(2):339.
Komatsu H, Tanji E, Sakata N, Aoki T, Motoi F, Naitoh T, et al. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. PLoS One. 2014;9(2):e87875.
Adsay NV, Adair CF, Heffess CS, Klimstra DS. Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol. 1996;20(8):980–94.
Basturk O, Chung SM, Hruban RH, Adsay NV, Askan G, Iacobuzio-Donahue C, et al. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch. 2016;469(5):523–32.
Patel SA, Adams R, Goldstein M, Moskaluk CA. Genetic analysis of invasive carcinoma arising in intraductal oncocytic papillary neoplasm of the pancreas. Am J Surg Pathol. 2002;26(8):1071–7.
Konigsrainer I, Glatzle J, Kloppel G, Konigsrainer A, Wehrmann M. Intraductal and cystic tubulopapillary adenocarcinoma of the pancreas--a possible variant of intraductal tubular carcinoma. Pancreas. 2008;36(1):92–5.
Yamaguchi H, Shimizu M, Ban S, Koyama I, Hatori T, Fujita I, et al. Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2009;33(8):1164–72.
Schlitter AM, Jang KT, Kloppel G, Saka B, Hong SM, Choi H, et al. Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol. 2015;28(9):1249–64.
Tajiri T, Tate G, Kunimura T, Inoue K, Mitsuya T, Yoshiba M, et al. Histologic and immunohistochemical comparison of intraductal tubular carcinoma, intraductal papillary-mucinous carcinoma, and ductal adenocarcinoma of the pancreas. Pancreas. 2004;29(2):116–22.
Tajiri T, Tate G, Inagaki T, Kunimura T, Inoue K, Mitsuya T, et al. Intraductal tubular neoplasms of the pancreas: histogenesis and differentiation. Pancreas. 2005;30(2):115–21.
Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shiratori K, Kawamura S, et al. Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol. 2011;35(12):1812–7.
Basturk O, Berger MF, Yamaguchi H, Adsay V, Askan G, Bhanot UK, et al. Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. Mod Pathol. 2017;30(12):1760–72.
Chatelain D, Paye F, Mourra N, Scoazec JY, Baudrimont M, Parc R, et al. Unilocular acinar cell cystadenoma of the pancreas an unusual acinar cell tumor. Am J Clin Pathol. 2002;118(2):211–4.
Albores-Saavedra J. Acinar cystadenoma of the pancreas: a previously undescribed tumor. Ann Diagn Pathol. 2002;6(2):113–5.
Khor TS, Badizadegan K, Ferrone C, Fernandez-del Castillo C, Desai GS, Saenz A, et al. Acinar cystadenoma of the pancreas: a clinicopathologic study of 10 cases including multilocular lesions with mural nodules. Am J Surg Pathol. 2012;36(11):1579–91.
Singhi AD, Norwood S, Liu TC, Sharma R, Wolfgang CL, Schulick RD, et al. Acinar cell cystadenoma of the pancreas: a benign neoplasm or non-neoplastic ballooning of acinar and ductal epithelium? Am J Surg Pathol. 2013;37(9):1329–35.
Couvelard A, Terris B, Hammel P, Palazzo L, Belghiti J, Levy P, et al. Acinar cystic transformation of the pancreas (or acinar cell cystadenoma), a rare and recently described entity. Ann Pathol. 2002;22(5):397–400.
Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16(9):815–37.
Hoorens A, Lemoine NR, McLellan E, Morohoshi T, Kamisawa T, Heitz PU, et al. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol. 1993;143(3):685–98.
La Rosa S, Adsay V, Albarello L, Asioli S, Casnedi S, Franzi F, et al. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol. 2012;36(12):1782–95.
Shorter NA, Glick RD, Klimstra DS, Brennan MF, MP LQ. Malignant pancreatic tumors in childhood and adolescence: the Memorial Sloan-Kettering experience, 1967 to present. J Pediatr Surg. 2002;37(6):887–92.
Burns WA, Matthews MJ, Hamosh M, Weide GV, Blum R, Johnson FB. Lipase-secreting acinar cell carcinoma of the pancreas with polyarthropathy. A light and electron microscopic, histochemical, and biochemical study. Cancer. 1974;33(4):1002–9.
Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol. 2002;20(24):4673–8.
Vakiani E, Young RH, Carcangiu ML, Klimstra DS. Acinar cell carcinoma of the pancreas metastatic to the ovary: a report of 4 cases. Am J Surg Pathol. 2008;32(10):1540–5.
Sigel CS, Klimstra DS. Cytomorphologic and immunophenotypical features of acinar cell neoplasms of the pancreas. Cancer Cytopathol. 2013;121(8):459–70.
Lowery MA, Klimstra DS, Shia J, Yu KH, Allen PJ, Brennan MF, et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist. 2011;16(12):1714–20.
Cantrell BB, Cubilla AL, Erlandson RA, Fortner J, Fitzgerald PJ. Acinar cell cystadenocarcinoma of human pancreas. Cancer. 1981;47(2):410–6.
Labate AM, Klimstra DL, Zakowski MF. Comparative cytologic features of pancreatic acinar cell carcinoma and islet cell tumor. Diagn Cytopathol. 1997;16(2):112–6.
Klimstra DS, Rosai J, Heffess CS. Mixed acinar-endocrine carcinomas of the pancreas. Am J Surg Pathol. 1994;18(8):765–78.
Ohike N, Kosmahl M, Kloppel G. Mixed acinar-endocrine carcinoma of the pancreas. A clinicopathological study and comparison with acinar-cell carcinoma. Virchows Arch. 2004;445(3):231–5.
Askan G, Deshpande V, Klimstra DS, Adsay V, Sigel C, Shia J, et al. Expression of markers of hepatocellular differentiation in pancreatic acinar cell neoplasms: a potential diagnostic pitfall. Am J Clin Pathol. 2016;146(2):163–9.
Ting DT, Deshpande V. Expression of albumin mRNA in primary hepatic neoplasms and acinar cell carcinoma. Am J Surg Pathol. 2015;39(8):1157–8.
Wang L, Basturk O, Chmielecki J, Ross J, Stephens P, Adsay V, et al. Development of BRAF FISH assay for the detection of BRAF gene rearrangements identified in pancreatic acinar cell carcinomas. Lab Investig. 2015-02-01;95(Supplemental 1):132–40.
Liu W, Shia J, Gönen M, Lowery MA, O’Reilly EM, Klimstra DS. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance. Pancreas. 2014;43(8):1264–70.
Karamurzin Y, Zeng Z, Stadler ZK, Zhang L, Ouansafi I, Al-Ahmadie HA, et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol. 2012;43(10):1677–87.
Terhune PG, Heffess CS, Longnecker DS. Only wild-type c-ki-ras codons 12, 13, and 61 in human pancreatic acinar cell carcinomas. Mol Carcinog. 1994;10(2):110–4.
Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer. 2001;84(2):253–62.
Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol. 2002;160(3):953–62.
Furlan D, Sahnane N, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, et al. APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation. Virchows Arch. 2014;464(5):553–64.
La Rosa S, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, Furlan D, et al. TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. Virchows Arch. 2016;468(3):289–96.
Klimstra DS, Wenig BM, Adair CF, Heffess CS. Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol. 1995;19(12):1371–89.
Palosaari D, Clayton F, Seaman J. Pancreatoblastoma in an adult. Arch Pathol Lab Med. 1986;110(7):650–2.
Dunn JL, Longnecker DS. Pancreatoblastoma in an older adult. Arch Pathol Lab Med. 1995;119(6):547–51.
Hoorens A, Gebhard F, Kraft K, Lemoine NR, Kloppel G. Pancreatoblastoma in an adult: its separation from acinar cell carcinoma. Virchows Arch. 1994;424(5):485–90.
Drut R, Jones MC. Congenital pancreatoblastoma in Beckwith-Wiedemann syndrome: an emerging association. Pediatr Pathol. 1988;8(3):331–9.
Muguerza R, Rodriguez A, Formigo E, Montero M, Vazquez JL, Paramo C, et al. Pancreatoblastoma associated with incomplete Beckwith-Wiedemann syndrome: case report and review of the literature. J Pediatr Surg. 2005;40(8):1341–4.
Bien E, Godzinski J, Dall'igna P, Defachelles AS, Stachowicz-Stencel T, Orbach D, et al. Pancreatoblastoma: a report from the European cooperative study group for paediatric rare tumours (EXPeRT). Eur J Cancer. 2011;47(15):2347–52.
Morohoshi T, Kanda M, Horie A, Chott A, Dreyer T, Kloppel G, et al. Immunocytochemical markers of uncommon pancreatic tumors. Acinar cell carcinoma, pancreatoblastoma, and solid cystic (papillary-cystic) tumor. Cancer. 1987;59(4):739–47.
Cingolani N, Shaco-Levy R, Farruggio A, Klimstra DS, Rosai J. Alpha-fetoprotein production by pancreatic tumors exhibiting acinar cell differentiation: study of five cases, one arising in a mediastinal teratoma. Hum Pathol. 2000;31(8):938–44.
Tanaka Y, Kato K, Notohara K, Nakatani Y, Miyake T, Ijiri R, et al. Significance of aberrant (cytoplasmic/nuclear) expression of beta-catenin in pancreatoblastoma. J Pathol. 2003;199(2):185–90.
Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol. 2001;159(5):1619–27.
Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS. Pancreatic acinar cell carcinomas with prominent ductal differentiation: mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol. 2010;34(4):510–8.
Yu R, Jih L, Zhai J, Nissen NN, Colquhoun S, Wolin E, et al. Mixed acinar-endocrine carcinoma of the pancreas: new clinical and pathological features in a contemporary series. Pancreas. 2013;42(3):429–35.
Ogbonna OH, Garcon MC, Syrigos KN, Saif MW. Mixed acinar-neuroendocrine carcinoma of the pancreas with neuroendocrine predominance. Case Rep Med. 2013;2013:705092.
Klimstra DS, Wenig BM, Heffess CS. Solid-pseudopapillary tumor of the pancreas: a typically cystic carcinoma of low malignant potential. Semin Diagn Pathol. 2000;17(1):66–80.
Kissane JM. Pancreatoblastoma and solid and cystic papillary tumor: two tumors related to pancreatic ontogeny. Semin Diagn Pathol. 1994;11(2):152–64.
Kloppel G, Morohoshi T, John HD, Oehmichen W, Opitz K, Angelkort A, et al. Solid and cystic acinar cell tumour of the pancreas. A tumour in young women with favourable prognosis. Virchows Arch A Pathol Anat Histol. 1981;392(2):171–83.
Pettinato G, Manivel JC, Ravetto C, Terracciano LM, Gould EW, di Tuoro A, et al. Papillary cystic tumor of the pancreas. A clinicopathologic study of 20 cases with cytologic, immunohistochemical, ultrastructural, and flow cytometric observations, and a review of the literature. Am J Clin Pathol. 1992;98(5):478–88.
Stommer P, Kraus J, Stolte M, Giedl J. Solid and cystic pancreatic tumors. Clinical, histochemical, and electron microscopic features in ten cases. Cancer. 1991;67(6):1635–41.
Matsunou H, Konishi F, Yamamichi N, Takayanagi N, Mukai M. Solid, infiltrating variety of papillary cystic neoplasm of the pancreas. Cancer. 1990;65(12):2747–57.
Kloppel G, Maurer R, Hofmann E, Luthold K, Oscarson J, Forsby N, et al. Solid-cystic (papillary-cystic) tumours within and outside the pancreas in men: report of two patients. Virchows Arch A Pathol Anat Histopathol. 1991;418(2):179–83.
Nishihara K, Nagoshi M, Tsuneyoshi M, Yamaguchi K, Hayashi I. Papillary cystic tumors of the pancreas. Assessment of their malignant potential. Cancer. 1993;71(1):82–92.
Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol. 2002;160(4):1361–9.
Chetty R, Serra S. Loss of expression of E-cadherin in solid pseudopapillary tumors of the pancreas. Pancreas. 2009;38(3):338. author reply −9.
Hibi T, Ojima H, Sakamoto Y, Kosuge T, Shimada K, Sano T, et al. A solid pseudopapillary tumor arising from the greater omentum followed by multiple metastases with increasing malignant potential. J Gastroenterol. 2006;41(3):276–81.
Zinner MJ, Shurbaji MS, Cameron JL. Solid and papillary epithelial neoplasms of the pancreas. Surgery. 1990;108(3):475–80.
Martin RC, Klimstra DS, Brennan MF, Conlon KC. Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol. 2002;9(1):35–40.
Orlando CA, Bowman RL, Loose JH. Multicentric papillary-cystic neoplasm of the pancreas. Arch Pathol Lab Med. 1991;115(9):958–60.
Albores-Saavedra J, Simpson KW, Bilello SJ. The clear cell variant of solid pseudopapillary tumor of the pancreas: a previously unrecognized pancreatic neoplasm. Am J Surg Pathol. 2006;30(10):1237–42.
Tang LH, Aydin H, Brennan MF, Klimstra DS. Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol. 2005;29(4):512–9.
Tanaka Y, Kato K, Notohara K, Hojo H, Ijiri R, Miyake T, et al. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res. 2001;61(23):8401–4.
Tiemann K, Heitling U, Kosmahl M, Kloppel G. Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q. Mod Pathol. 2007;20(9):955–60.
Serra S, Chetty R. Revision 2: an immunohistochemical approach and evaluation of solid pseudopapillary tumour of the pancreas. J Clin Pathol. 2008;61(11):1153–9.
Zamboni G, Bonetti F, Scarpa A, Pelosi G, Doglioni C, Iannucci A, et al. Expression of progesterone receptors in solid-cystic tumour of the pancreas: a clinicopathological and immunohistochemical study of ten cases. Virchows Arch A Pathol Anat Histopathol. 1993;423(6):425–31.
Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.
Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–23.
Zee SY, Hochwald SN, Conlon KC, Brennan MF, Klimstra DS. Pleomorphic pancreatic endocrine neoplasms: a variant commonly confused with adenocarcinoma. Am J Surg Pathol. 2005;29(9):1194–200.
Gould VE, Wiedenmann B, Lee I, Schwechheimer K, Dockhorn-Dworniczak B, Radosevich JA, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol. 1987;126(2):243–57.
Lloyd RV, Mervak T, Schmidt K, Warner TF, Wilson BS. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol. 1984;8(8):607–14.
Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203.
Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146(2):453–60. e5.
Reyes CV, Wang T. Undifferentiated small cell carcinoma of the pancreas: a report of five cases. Cancer. 1981;47(10):2500–2.
Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38(4):437–47.
Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–84.
Gramlich Tea. In: Mills IS, editor. Histology for pathologists. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 24.
Witkiewicz A, Galler A, Yeo CJ, Gross SD. Gangliocytic paraganglioma: case report and review of the literature. J Gastrointest Surg. 2007;11(10):1351–4.
Stringer Mea. In: Standring S, editor. Gray’s anatomy: the anatomical basis of clinical practice. 41st ed. Philadelphia: Elsevier; 2013.
Costacurta L. Anatomical and functional aspects of the human suspensory muscle of the duodenum. Acta Anat (Basel). 1972;82(1):34–46.
Thompson JS, Langnas AN, Pinch LW, Kaufman S, Quigley EM, Vanderhoof JA. Surgical approach to short-bowel syndrome. Experience in a population of 160 patients. Ann Surg. 1995;222(4):600–5. discussion 5-7.
Marsh MN, Rostami K. What is normal intestinal mucosa? Gastroenterology. 2016;151(5):784–8.
Rubin W. The epithelial “membrane” of the small intestine. Am J Clin Nutr. 1971;24(1):45–64.
Dobbins WO 3rd. Human intestinal intraepithelial lymphocytes. Gut. 1986;27(8):972–85.
Ferguson A, Murray D. Quantitation of intraepithelial lymphocytes in human jejunum. Gut. 1971;12(12):988–94.
Selby WS, Janossy G, Bofill M, Jewell DP. Lymphocyte subpopulations in the human small intestine. The findings in normal mucosa and in the mucosa of patients with adult coeliac disease. Clin Exp Immunol. 1983;52(1):219–28.
Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomark Prev. 1998;7(3):243–51.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
Haselkorn T, Whittemore AS, Lilienfeld DE. Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control. 2005;16(7):781–7.
Howe JR, Karnell LH, Menck HR, Scott-Conner C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer. 1999;86(12):2693–706.
Severson RK, Schenk M, Gurney JG, Weiss LK, Demers RY. Increasing incidence of adenocarcinomas and carcinoid tumors of the small intestine in adults. Cancer Epidemiol Biomark Prev. 1996;5(2):81–4.
Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249(1):63–71.
Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10.
Wright DH. The major complications of coeliac disease. Baillieres Clin Gastroenterol. 1995;9(2):351–69.
Howdle PD, Jalal PK, Holmes GK, Houlston RS. Primary small-bowel malignancy in the UK and its association with coeliac disease. QJM. 2003;96(5):345–53.
Wheeler JM, Warren BF, Mortensen NJ, Kim HC, Biddolph SC, Elia G, et al. An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut. 2002;50(2):218–23.
Aparicio T, Svrcek M, Zaanan A, Beohou E, Laforest A, Afchain P, et al. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer. 2013;109(12):3057–66.
Breuhahn K, Singh S, Schirmacher P, Blaker H. Large-scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas, suggesting divergent molecular pathways of small and large intestinal carcinogenesis. J Pathol. 2008;215(3):300–7.
Arai M, Shimizu S, Imai Y, Nakatsuru Y, Oda H, Oohara T, et al. Mutations of the Ki-ras, p53 and APC genes in adenocarcinomas of the human small intestine. Int J Cancer. 1997;70(4):390–5.
Blaker H, von Herbay A, Penzel R, Gross S, Otto HF. Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene. Oncogene. 2002;21(1):158–64.
Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, et al. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur J Cancer. 2014;50(10):1740–6.
Koornstra JJ. Small bowel endoscopy in familial adenomatous polyposis and Lynch syndrome. Best Pract Res Clin Gastroenterol. 2012;26(3):359–68.
Vasen HF, Bulow S, Myrhoj T, Mathus-Vliegen L, Griffioen G, Buskens E, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut. 1997;40(6):716–9.
Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010;199(6):797–803.
Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010;102(1):144–50.
Svrcek M, Jourdan F, Sebbagh N, Couvelard A, Chatelain D, Mourra N, et al. Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray study. J Clin Pathol. 2003;56(12):898–903.
Planck M, Ericson K, Piotrowska Z, Halvarsson B, Rambech E, Nilbert M. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. Cancer. 2003;97(6):1551–7.
Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, Tijssen M, et al. High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas. Clin Cancer Res. 2010;16(5):1391–401.
Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46(2):97–104.
Palascak-Juif V, Bouvier AM, Cosnes J, Flourie B, Bouche O, Cadiot G, et al. Small bowel adenocarcinoma in patients with Crohn’s disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis. 2005;11(9):828–32.
Askling J, Linet M, Gridley G, Halstensen TS, Ekstrom K, Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002;123(5):1428–35.
Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy in patients with celiac disease. Am J Med. 2003;115(3):191–5.
Talamonti MS, Goetz LH, Rao S, Joehl RJ. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg. 2002;137(5):564–70. discussion 70-1.
Masselli G, Polettini E, Casciani E, Bertini L, Vecchioli A, Gualdi G. Small-bowel neoplasms: prospective evaluation of MR enteroclysis. Radiology. 2009;251(3):743–50.
Ross A, Mehdizadeh S, Tokar J, Leighton JA, Kamal A, Chen A, et al. Double balloon enteroscopy detects small bowel mass lesions missed by capsule endoscopy. Dig Dis Sci. 2008;53(8):2140–3.
Fischer HP, Zhou H. Pathogenesis of carcinoma of the papilla of Vater. J Hepato-Biliary-Pancreat Surg. 2004;11(5):301–9.
Law JK. New developments in small bowel enteroscopy. Curr Opin Gastroenterol. 2016;32:387.
Saurin JC, Pilleul F, Soussan EB, Maniere T, D'Halluin PN, Gaudric M, et al. Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with lynch syndrome. Endoscopy. 2010;42(12):1057–62.
Standards of Practice C, Adler DG, Qureshi W, Davila R, Gan SI, Lichtenstein D, et al. The role of endoscopy in ampullary and duodenal adenomas. Gastrointest Endosc. 2006;64(6):849–54.
Meneghetti AT, Safadi B, Stewart L, Way LW. Local resection of ampullary tumors. J Gastrointest Surg. 2005;9(9):1300–6.
Zadorova Z, Dvofak M, Hajer J. Endoscopic therapy of benign tumors of the papilla of Vater. Endoscopy. 2001;33(4):345–7.
Zhang MQ, Lin F, Hui P, Chen ZM, Ritter JH, Wang HL. Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. Am J Clin Pathol. 2007;128(5):808–16.
Chen ZM, Ritter JH, Wang HL. Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol. 2005;29(7):890–6.
Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6(5):322–7.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67(6):2643–8.
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705–12.
Allegra CJ, Rumble RB, Schilsky RL. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015 summary. J Oncol Pract. 2016;12(2):180–1.
Cancer AJCO. AJCC cancer staging manual. 8th ed. Chicago: Springer; 2016.
Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 2000;135(6):635–41. discussion 41-2.
Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann Surg. 1998;228(1):87–94.
Kimura W, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. J Hepato-Biliary-Pancreat Surg. 2004;11(4):223–31.
He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford). 2014;16(1):83–90.
Chen SC, Shyr YM, Wang SE. Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. HPB (Oxford). 2013;15(12):951–7.
Chandrasegaram MD, Chiam SC, Chen JW, Khalid A, Mittinty ML, Neo EL, et al. Distribution and pathological features of pancreatic, ampullary, biliary and duodenal cancers resected with pancreaticoduodenectomy. World J Surg Oncol. 2015;13:85.
Sperti C, Pasquali C, Piccoli A, Sernagiotto C, Pedrazzoli S. Radical resection for ampullary carcinoma: long-term results. Br J Surg. 1994;81(5):668–71.
Talamini MA, Moesinger RC, Pitt HA, Sohn TA, Hruban RH, Lillemoe KD, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg. 1997;225(5):590–9. discussion 9-600.
Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226(3):248–57. discussion 57-60.
Bouvet M, Gamagami RA, Gilpin EA, Romeo O, Sasson A, Easter DW, et al. Factors influencing survival after resection for periampullary neoplasms. Am J Surg. 2000;180(1):13–7.
Chang MC, Chang YT, Tien YW, Sun CT, Wu MS, Lin JT. Distinct chromosomal aberrations of ampulla of Vater and pancreatic head cancers detected by laser capture microdissection and comparative genomic hybridization. Oncol Rep. 2005;14(4):867–72.
Ohike N, Kim GE, Tajiri T, Krasinskas A, Basturk O, Coban I, et al. Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases. Am J Surg Pathol. 2010;34(12):1731–48.
Adsay V, Ohike N, Tajiri T, Kim GE, Krasinskas A, Balci S, et al. Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol. 2012;36(11):1592–608.
Reid MD, Balci S, Ohike N, Xue Y, Kim GE, Tajiri T, et al. Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Mod Pathol. 2016;29(12):1575–85.
Cancer IAfRo. In: Bosman FT, editor. WHO classification of tumors of the digestive system. 4th ed. Lyon: IARC Press; 2010.
Chen YY, Li AF, Huang KH, Lan YT, Chen MH, Chao Y, et al. Adenosquamous carcinoma of the stomach and review of the literature. Pathol Oncol Res. 2015;21(3):547–51.
Komatsu H, Egawa S, Motoi F, Morikawa T, Sakata N, Naitoh T, et al. Clinicopathological features and surgical outcomes of adenosquamous carcinoma of the pancreas: a retrospective analysis of patients with resectable stage tumors. Surg Today. 2015;45(3):297–304.
Masoomi H, Ziogas A, Lin BS, Barleben A, Mills S, Stamos MJ, et al. Population-based evaluation of adenosquamous carcinoma of the colon and rectum. Dis Colon Rectum. 2012;55(5):509–14.
Sreenarasimhaiah J, Hoang MP. Esophageal squamous cell carcinoma with metastasis to the ampulla. Gastrointest Endosc. 2005;62(2):310–1. discussion 1.
Lee TH, Park SH, Lee CK, Lee SH, Chung IK, Kim SJ, et al. Ampulla of Vater metastasis from recurrent uterine cervix carcinoma presenting as groove pancreatitis. Gastrointest Endosc. 2011;73(2):362–3.
Buyukcelik A, Ensari A, Sarioglu M, Isikdogan A, Icli F. Squamous cell carcinoma of the larynx metastasized to the ampulla of Vater. Report of a case. Tumori. 2003;89(2):199–201.
Murakami T, Yao T, Mitomi H, Morimoto T, Ueyama H, Matsumoto K, et al. Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases. Gastric Cancer. 2016;19(2):498–507.
Gardiner GW, Lajoie G, Keith R. Hepatoid adenocarcinoma of the papilla of Vater. Histopathology. 1992;20(6):541–4.
Sato Y, Tominaga H, Tangoku A, Hamanaka Y, Yamashita Y, Suzuki T. Alpha-fetoprotein-producing cancer of the ampulla of Vater. Hepato-Gastroenterology. 1992;39(6):566–9.
Sakamoto K, Watanabe M, De La Cruz C, Honda H, Ise H, Mitsui K, et al. Primary invasive micropapillary carcinoma of the colon. Histopathology. 2005;47(5):479–84.
De la Cruz C, Moriya T, Endoh M, Watanabe M, Takeyama J, Yang M, et al. Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study. Pathol Int. 2004;54(2):90–6.
Michal M, Skalova A, Mukensnabl P. Micropapillary carcinoma of the parotid gland arising in mucinous cystadenoma. Virchows Arch. 2000;437(4):465–8.
Amin MB, Tamboli P, Merchant SH, Ordonez NG, Ro J, Ayala AG, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 2002;26(3):358–64.
Roh JH, Srivastava A, Lauwers GY, An J, Jang KT, Park CK, et al. Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol. 2010;34(8):1139–46.
Khayyata S, Basturk O, Adsay NV. Invasive micropapillary carcinomas of the ampullo-pancreatobiliary region and their association with tumor-infiltrating neutrophils. Mod Pathol. 2005;18(11):1504–11.
Fujita T, Konishi M, Gotohda N, Takahashi S, Nakagohri T, Kojima M, et al. Invasive micropapillary carcinoma of the ampulla of Vater with extensive lymph node metastasis: report of a case. Surg Today. 2010;40(12):1197–200.
Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol. 2004;17(9):1045–50.
Lee JH, Kim JH, Choi JW, Kim YS. The presence of a micropapillary component predicts aggressive behaviour in early and advanced gastric adenocarcinomas. Pathology. 2010;42(6):560–3.
McQuitty E, Ro JY, Truong LD, Shen SS, Zhai Q, Ayala AG. Lymphovascular invasion in micropapillary urothelial carcinoma: a study of 22 cases. Arch Pathol Lab Med. 2012;136(6):635–9.
Terada T. Primary signet-ring cell carcinoma of the ampulla of Vater: a case report with an immunohistochemical study. Appl Immunohistochem Mol Morphol. 2012;20(4):427–8.
Wakasugi M, Tanemura M, Furukawa K, Murata M, Miyazaki M, Oshita M, et al. Signet ring cell carcinoma of the ampulla of vater: Report of a case and a review of the literature. Int J Surg Case Rep. 2015;12:108–11.
Molberg KH, Heffess C, Delgado R, Albores-Saavedra J. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region. Cancer. 1998;82(7):1279–87.
Hechtman JF, Liu W, Sadowska J, Zhen L, Borsu L, Arcila ME, et al. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Mod Pathol. 2015;28(8):1123–9.
Nakai T, Koh K, Kawabe T, Son E, Yoshikawa H, Yasutomi M. Importance of microperineural invasion as a prognostic factor in ampullary carcinoma. Br J Surg. 1997;84(10):1399–401.
Willett CG, Warshaw AL, Convery K, Compton CC. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet. 1993;176(1):33–8.
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–12.
Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.
Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713–34.
Vinik AI, Anthony L, Boudreaux JP, Go VL, O’Dorisio TM, Ruszniewski P, et al. Neuroendocrine tumors: a critical appraisal of management strategies. Pancreas. 2010;39(6):801–18.
Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer. 2004;90(9):1720–6.
Van Landingham SB, Kluppel S, Symmonds R Jr, Snyder SK. Coexisting carcinoid tumor and Crohn’s disease. J Surg Oncol. 1983;24(4):310–4.
Moyana TN, Shukoor S. Gastrointestinal endocrine cell hyperplasia in celiac disease: a selective proliferative process of serotonergic cells. Mod Pathol. 1991;4(4):419–23.
Di Sabatino A, Giuffrida P, Vanoli A, Luinetti O, Manca R, Biancheri P, et al. Increase in neuroendocrine cells in the duodenal mucosa of patients with refractory celiac disease. Am J Gastroenterol. 2014;109(2):258–69.
Anlauf M, Garbrecht N, Henopp T, Schmitt A, Schlenger R, Raffel A, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol. 2006;12(34):5440–6.
Anlauf M, Perren A, Henopp T, Rudolf T, Garbrecht N, Schmitt A, et al. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut. 2007;56(5):637–44.
Perren A, Anlauf M, Henopp T, Rudolph T, Schmitt A, Raffel A, et al. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab. 2007;92(3):1118–28.
Anlauf M, Perren A, Meyer CL, Schmid S, Saremaslani P, Kruse ML, et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology. 2005;128(5):1187–98.
Kloppel G, Anlauf M, Perren A. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol. 2007;18(3):150–5.
Feldman JM. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem. 1986;32(5):840–4.
Feldman JM. Increased dopamine production in patients with carcinoid tumors. Metabolism. 1985;34(3):255–60.
Alumets J, Hakanson R, Ingemansson S, Sundler F. Substance P and 5-HT in granules isolated from an intestinal argentaffin carcinoid. Histochemistry. 1977;52(3):217–22.
Oates JA, Pettinger WA, Doctor RB. Evidence for the release of bradykinin in carcinoid syndrome. J Clin Invest. 1966;45(2):173–8.
Theodorsson-Norheim E, Norheim I, Oberg K, Brodin E, Lundberg JM, Tatemoto K, et al. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients. Biochem Biophys Res Commun. 1985;131(1):77–83.
Lucas KJ, Feldman JM. Flushing in the carcinoid syndrome and plasma kallikrein. Cancer. 1986;58(10):2290–3.
Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34(3):300–13.
Debas HT, Soon-Shiong P, McKenzie AD, Bogoch A, Greig JH, Dunn WL, et al. Use of secretin in the roentgenologic and biochemical diagnosis of duodenal gastrinoma. Am J Surg. 1983;145(3):408–11.
Passaro E Jr, Howard TJ, Sawicki MP, Watt PC, Stabile BE. The origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg. 1998;133(1):13–6. discussion 7.
Deveney CW, Deveney KE, Stark D, Moss A, Stein S, Way LW. Resection of gastrinomas. Ann Surg. 1983;198(4):546–53.
Friesen SR. The development of endocrinopathies in the prospective screening of two families with multiple endocrine adenopathy, type I. World J Surg. 1979;3(6):753–64.
Friesen SR. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am. 1987;67(2):379–93.
Perry RR, Feliberti E, Vinik A. Gastrinoma Zollinger-Ellison-Syndrome. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth: MDText.com; 2000.
Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13(1):78–108.
Zollinger RM. Gastrinoma: factors influencing prognosis. Surgery. 1985;97(1):49–54.
Stabile BE, Passaro E Jr. Benign and malignant gastrinoma. Am J Surg. 1985;149(1):144–50.
Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology. 1989;97(4):827–36.
Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999;17(2):615–30.
Barreras RF, Mack E, Goodfriend T, Damm M. Resection of gastrinoma in the Zollinger-Ellison syndrome. Gastroenterology. 1982;82(5 Pt 1):953–6.
Kloppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2005;19(4):507–17.
Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR, Raskin P, et al. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med. 1979;301(6):285–92.
Ganda OP, Weir GC, Soeldner JS, Legg MA, Chick WL, Patel YC, et al. “Somatostatinoma”: a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med. 1977;296(17):963–7.
Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B, Raffel A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008;15(1):229–41.
Crain EL Jr, Thorn GW. Functioning pancreatic islet cell adenomas; a review of the literature and presentation of two new differential tests. Medicine (Baltimore). 1949;28(4):427–47.
Suzuki H, Kuwano H, Masuda N, Hashimoto S, Kanoh K, Nomoto K, et al. Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas. Hepato-Gastroenterology. 2008;55(85):1242–5.
Luna IE, Monrad N, Binderup T, Boisen Thoegersen C, Hilsted L, Jensen C, et al. Somatostatin-immunoreactive pancreaticoduodenal neuroendocrine neoplasms: twenty-three cases evaluated according to the WHO 2010 classification. Neuroendocrinology. 2016;103(5):567–77.
Tanaka S, Yamasaki S, Matsushita H, Ozawa Y, Kurosaki A, Takeuchi K, et al. Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int. 2000;50(2):146–52.
Vinik A, Feliberti E, Perry RR. Somatostatinoma. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth: MDText.com; 2000.
Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut. 1998;42(6):792–4.
Gonzalez RS, Liu EH, Alvarez JR, Ayers GD, Washington MK, Shi C. Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? Mod Pathol. 2014;27(9):1288–95.
Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36(6):1419–31.
Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol. 1991;30(4):547–53.
Arnold R, Muller H, Schade-Brittinger C, Rinke A, Klose K, Barth P, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(15_suppl):4508.
Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657–66.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77.
Okubo Y, Yokose T, Motohashi O, Miyagi Y, Yoshioka E, Suzuki M, et al. Duodenal rare neuroendocrine tumor: clinicopathological characteristics of patients with gangliocytic paraganglioma. Gastroenterol Res Pract. 2016;2016:5257312.
Park HK, Han HS. Duodenal gangliocytic paraganglioma with lymph node metastasis. Arch Pathol Lab Med. 2016;140(1):94–8.
Okubo Y, Wakayama M, Nemoto T, Kitahara K, Nakayama H, Shibuya K, et al. Literature survey on epidemiology and pathology of gangliocytic paraganglioma. BMC Cancer. 2011;11:187.
Mann CM, Bramhall SR, Buckels JA, Taniere P. An unusual case of duodenal obstruction-gangliocytic paraganglioma. J Hepato-Biliary-Pancreat Surg. 2009;16(4):562–5.
Tomic S, Warner T. Pancreatic somatostatin-secreting gangliocytic paraganglioma with lymph node metastases. Am J Gastroenterol. 1996;91(3):607–8.
Netter FH. Atlas of human anatomy. 4th ed. Philadelphia: Saunders/Elsevier; 2006. p. 548. 47 p.
Mills SE, editor. Histology for pathologists. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2012.
Shamsuddin AM, Phelps PC, Trump BF. Human large intestinal epithelium: light microscopy, histochemistry, and ultrastructure. Hum Pathol. 1982;13(9):790–803.
Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian theory of the origin of the four epithelial cell types. Am J Anat. 1974;141(4):537–61.
Ramachandran A, Madesh M, Balasubramanian KA. Apoptosis in the intestinal epithelium: its relevance in normal and pathophysiological conditions. J Gastroenterol Hepatol. 2000;15(2):109–20.
Merker SR, Weitz J, Stange DE. Gastrointestinal organoids: how they gut it out. Dev Biol. 2016;420(2):239–50.
He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet. 2004;36(10):1117–21.
Symonds DA. Paneth cell metaplasia in diseases of the colon and rectum. Arch Pathol. 1974;97(6):343–7.
Donnellan WL. The structure of the colonic mucosa. The epithelium and subepithelial reticulohistiocytic complex. Gastroenterology. 1965;49(5):496–514.
Watanabe H, Margulis AR, Harter L. The occurrence of lymphoid nodules in the colon of adults. J Clin Gastroenterol. 1983;5(6):535–9.
Azzopardi JG, Evans DJ. Mucoprotein-containing histiocytes (muciphages) in the rectum. J Clin Pathol. 1966;19(4):368–74.
Bethesda, MD: National Cancer Institute; 2017. pp. 1–6, updated November 2016. Available from: https://seer.cancer.gov/csr/1975_2014/.
Cancer facts and figures London, England: World Cancer Research Fund International; Available from: www.wcrf.org.
Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11 [Internet] Lyon, France: International Agency for Research on Cancer; 2013 [Version 1.0]: Available from: http://globocan.iarc.fr/.
Lee YC, Lee YL, Chuang JP, Lee JC. Differences in survival between colon and rectal cancer from SEER data. PLoS One. 2013;8(11):e78709.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J Natl Cancer Inst. 2017;109(8)
Ballester V, Rashtak S, Boardman L. Clinical and molecular features of young-onset colorectal cancer. World J Gastroenterol. 2016;22(5):1736–44.
Ahnen DJ, Wade SW, Jones WF, Sifri R, Mendoza Silveiras J, Greenamyer J, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216–24.
Astin M, Griffin T, Neal RD, Rose P, Hamilton W. The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. Br J Gen Pract. 2011;61(586):e231–43.
Turati F, Bravi F, Di Maso M, Bosetti C, Polesel J, Serraino D, et al. Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and colorectal cancer risk. Eur J Cancer. 2017;85:86–94.
Shaukat A, Dostal A, Menk J, Church TR. BMI is a risk factor for colorectal cancer mortality. Dig Dis Sci. 2017;62(9):2511–7.
Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2007;121(9):2065–72.
Chang LC, Wu MS, Tu CH, Lee YC, Shun CT, Chiu HM. Metabolic syndrome and smoking may justify earlier colorectal cancer screening in men. Gastrointest Endosc. 2014;79(6):961–9.
Schmid D, Behrens G, Matthews CE, Leitzmann MF. Physical activity and risk of colon cancer in diabetic and nondiabetic US adults. Mayo Clin Proc. 2016;91(12):1693–705.
Solomon BL, Whitman T, Wood ME. Contribution of extended family history in assessment of risk for breast and colon cancer. BMC Fam Pract. 2016;17(1):126.
Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331(25):1669–74.
Montazeri Z, Theodoratou E, Nyiraneza C, Timofeeva M, Chen W, Svinti V, et al. Systematic meta-analyses and field synopsis of genetic association studies in colorectal adenomas. Int J Epidemiol. 2016;45(1):186–205.
Tarraga Lopez PJ, Albero JS, Rodriguez-Montes JA. Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol. 2014;7:33–46.
Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256–66.
Bae JM, Kim JH, Kang GH. Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med. 2016;140(5):406–12.
Stachler MD, Rinehart E, Lindeman N, Odze R, Srivastava A. Novel molecular insights from routine genotyping of colorectal carcinomas. Hum Pathol. 2015;46(4):507–13.
East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 2017;66(7):1181–96.
Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386(6625):623–7.
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681–6.
Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138(6):2088–100.
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108–13.
Patel SS, Kilgore ML. Cost effectiveness of colorectal cancer screening strategies. Cancer Control. 2015;22(2):248–58.
Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130(6):1872–85.
Mahajan D, Downs-Kelly E, Liu X, Pai RK, Patil DT, Rybicki L, et al. Reproducibility of the villous component and high-grade dysplasia in colorectal adenomas <1 cm: implications for endoscopic surveillance. Am J Surg Pathol. 2013;37(3):427–33.
Panarelli NC, Schreiner AM, Brandt SM, Shepherd NA, Yantiss RK. Histologic features and cytologic techniques that aid pathologic stage assessment of colonic adenocarcinoma. Am J Surg Pathol. 2013;37(8):1252–8.
Shepherd NA, Bussey HJ, Jass JR. Epithelial misplacement in Peutz-Jeghers polyps. A diagnostic pitfall. Am J Surg Pathol. 1987;11(10):743–9.
Backes Y, Moons LM, Novelli MR, van Bergeijk JD, Groen JN, Seerden TC, et al. Diagnosis of T1 colorectal cancer in pedunculated polyps in daily clinical practice: a multicenter study. Mod Pathol. 2017;30(1):104–12.
Benizri EI, Bereder JM, Rahili A, Bernard JL, Vanbiervliet G, Filippi J, et al. Additional colectomy after colonoscopic polypectomy for T1 colon cancer: a fine balance between oncologic benefit and operative risk. Int J Color Dis. 2012;27(11):1473–8.
Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum. 2002;45(2):200–6.
Netzer P, Forster C, Biral R, Ruchti C, Neuweiler J, Stauffer E, et al. Risk factor assessment of endoscopically removed malignant colorectal polyps. Gut. 1998;43(5):669–74.
Seitz U, Bohnacker S, Seewald S, Thonke F, Brand B, Braiutigam T, et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum. 2004;47(11):1789–96. discussion 96-7.
Pai RK, Chen Y, Jakubowski MA, Shadrach BL, Plesec TP, Pai RK. Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. Mod Pathol. 2017;30(1):113–22.
Rashtak S, Rego R, Sweetser SR, Sinicrope FA. Sessile serrated polyps and colon cancer prevention. Cancer Prev Res (Phila). 2017;10(5):270–8.
Yang HM, Mitchell JM, Sepulveda JL, Sepulveda AR. Molecular and histologic considerations in the assessment of serrated polyps. Arch Pathol Lab Med. 2015;139(6):730–41.
Choi EY, Appelman HD. A historical perspective and expose on serrated polyps of the colorectum. Arch Pathol Lab Med. 2016;140(10):1079–84.
Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107(9):1315–29. quiz 4, 30.
Yantiss RK, Goldman H, Odze RD. Hyperplastic polyp with epithelial misplacement (inverted hyperplastic polyp): a clinicopathologic and immunohistochemical study of 19 cases. Mod Pathol. 2001;14(9):869–75.
Kawasaki K, Kurahara K, Oshiro Y, Yanai S, Kobayashi H, Nakamura S, et al. Clinicopathologic features of inverted serrated lesions of the large bowel. Digestion. 2016;93(4):280–7.
He EY, Wyld L, Sloane MA, Canfell K, Ward RL. The molecular characteristics of colonic neoplasms in serrated polyposis: a systematic review and meta-analysis. J Pathol Clin Res. 2016;2(3):127–37.
Network NCC. Anal Carcinoma (Version 2.2017 – April 20, 2017). Available from: https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf.
Schoen RE, Akpan IM. Whither the hyperplastic and serrated polyp? Gastrointest Endosc. 2016;83(3):563–5.
Glatz K, Pritt B, Glatz D, Hartmann A, O’Brien MJ, Blaszyk H. A multinational, internet-based assessment of observer variability in the diagnosis of serrated colorectal polyps. Am J Clin Pathol. 2007;127(6):938–45.
Khalid O, Radaideh S, Cummings OW, O’Brien MJ, Goldblum JR, Rex DK. Reinterpretation of histology of proximal colon polyps called hyperplastic in 2001. World J Gastroenterol. 2009;15(30):3767–70.
Vayrynen SA, Vayrynen JP, Klintrup K, Makela J, Tuomisto A, Makinen MJ. Ectopic crypt foci in conventional and serrated colorectal polyps. J Clin Pathol. 2016;69(12):1063–9.
Hafezi-Bakhtiari S, Wang LM, Colling R, Serra S, Chetty R. Histological overlap between colorectal villous/tubulovillous and traditional serrated adenomas. Histopathology. 2015;66(2):308–13.
Kalimuthu SN, Serra S, Hafezi-Bakhtiari S, Colling R, Wang LM, Chetty R. Mucin-rich variant of traditional serrated adenoma: a distinct morphological variant. Histopathology. 2017;71(2):208–16.
Bettington ML, Walker NI, Rosty C, Brown IS, Clouston AD, McKeone DM, et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol. 2015;28(3):414–27.
Yantiss RK, Oh KY, Chen YT, Redston M, Odze RD. Filiform serrated adenomas: a clinicopathologic and immunophenotypic study of 18 cases. Am J Surg Pathol. 2007;31(8):1238–45.
Chetty R, Vajpeyi R, Penwick JL. Psammomatous melanotic schwannoma presenting as colonic polyps. Virchows Arch. 2007;451(3):717–20.
Liu C, Walker NI, Leggett BA, Whitehall VL, Bettington ML, Rosty C. Sessile serrated adenomas with dysplasia: morphological patterns and correlations with MLH1 immunohistochemistry. Mod Pathol. 2017;30:1728.
Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Gastroenterology. 2017;153(1):307–23.
Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep. 2012;14(5):428–38.
Hemminki K, Chen B. Familial risk for colorectal cancers are mainly due to heritable causes. Cancer Epidemiol Biomark Prev. 2004;13(7):1253–6.
Esteban-Jurado C, Garre P, Vila M, Lozano JJ, Pristoupilova A, Beltran S, et al. New genes emerging for colorectal cancer predisposition. World J Gastroenterol. 2014;20(8):1961–71.
Da Silva FC, Wernhoff P, Dominguez-Barrera C, Dominguez-Valentin M. Update on hereditary colorectal cancer. Anticancer Res. 2016;36(9):4399–405.
Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293(16):1979–85.
Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol. 2009;33(1):126–33.
Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1(3):207–16.
Egoavil C, Juarez M, Guarinos C, Rodriguez-Soler M, Hernandez-Illan E, Alenda C, et al. Increased risk of colorectal cancer in patients with multiple serrated polyps and their first-degree relatives. Gastroenterology. 2017;153(1):106–12. e2.
IJspeert JE, Rana SA, Atkinson NS, van Herwaarden YJ, Bastiaansen BA, van Leerdam ME, et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut. 2017;66(2):278–84.
Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut. 2010;59(8):1094–100.
Carballal S, Rodriguez-Alcalde D, Moreira L, Hernandez L, Rodriguez L, Rodriguez-Moranta F, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut. 2016;65(11):1829–37.
Colliver DW, Crawford NP, Eichenberger MR, Zacharius W, Petras RE, Stromberg AJ, et al. Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp Mol Pathol. 2006;80(1):1–10.
Tanaka T, Kobunai T, Yamamoto Y, Emoto S, Murono K, Kaneko M, et al. Colitic cancer develops through mutational alteration distinct from that in sporadic colorectal cancer: a comparative analysis of mutational rates at each step. Cancer Genomics Proteomics. 2017;14(5):341–8.
Castano-Milla CCM, Gisbert JP. Systemic review with meta-analysis; the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):645–59.
Kinugasa T, Akagi Y. Status of colitis-associated cancer in ulcerative colitis. World J Gastrointest Oncol. 2016;8(4):351–7.
Higashi D, Futami K, Ishibashi Y, Egawa Y, Maekawa T, Matsui T, et al. Clinical course of colorectal cancer in patients with ulcerative colitis. Anticancer Res. 2011;31(7):2499–504.
Levi GS, Harpaz N. Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease. Am J Surg Pathol. 2006;30(8):1022–9.
Hornick JL. Manual of surgical pathology. 3rd ed. Philadelphia: Elsevier Saunders; 2010.
Kakar S, Chanjuan S, Berho M, Driman D, Fitzgibbons P, Frankel W, Hill K, Jessup J, Kransinskas A, Washington M. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum 2016 [4.0.0.1]:Available from: http://www.cap.org/web/oracle/webcenter/portalapp/pagehierarchy/cancer_protocol_templates.jspx?_afrLoop=63660215376515 - !%40%40%3F_afrLoop%3D63660215376515%26_adf.ctrl-state%3Driqh4s1xm_4.
Hav M, Libbrecht L, Ferdinande L, Geboes K, Pattyn P, Cuvelier CA. Pathologic assessment of rectal carcinoma after neoadjuvant radio(chemo)therapy: prognostic implications. Biomed Res Int. 2015;2015:574540.
Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235(4):449–57.
Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Color Dis. 2006;8(9):800–7.
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.
Parfitt JR, Driman DK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol. 2007;60(8):849–55.
Gorog D, Nagy P, Peter A, Perner F. Influence of obesity on lymph node recovery from rectal resection specimens. Pathol Oncol Res. 2003;9(3):180–3.
Wijesuriya RE, Deen KI, Hewavisenthi J, Balawardana J, Perera M. Neoadjuvant therapy for rectal cancer down-stages the tumor but reduces lymph node harvest significantly. Surg Today. 2005;35(6):442–5.
Betge J, Harbaum L, Pollheimer MJ, Lindtner RA, Kornprat P, Ebert MP, et al. Lymph node retrieval in colorectal cancer: determining factors and prognostic significance. Int J Color Dis. 2017;32(7):991–8.
Arnold A, Kloor M, Jansen L, Chang-Claude J, Brenner H, von Winterfeld M, et al. The association between microsatellite instability and lymph node count in colorectal cancer. Virchows Arch. 2017;471(1):57–64.
Choi JP, Park IJ, Lee BC, Hong SM, Lee JL, Yoon YS, et al. Variability in the lymph node retrieval after resection of colon cancer: influence of operative period and process. Medicine (Baltimore). 2016;95(31):e4199.
Solon JG, Cahalane A, Burke JP, Gibbons D, McCann JW, Martin ST, et al. A radiological and pathological assessment of ileocolic pedicle length as a predictor of lymph node retrieval following right hemicolectomy for caecal cancer. Tech Coloproctol. 2016;20(8):545–50.
Lavy R, Hershkovitz Y, Kapiev A, Chikman B, Shapira Z, Poluksht N, et al. A comparative study on two different pathological methods to retrieve lymph nodes following gastrectomy. Int J Surg. 2014;12(7):725–8.
Ong ML, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg. 2016;8(3):179–92.
Rossler O, Betge J, Harbaum L, Mrak K, Tschmelitsch J, Langner C. Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients. Mod Pathol. 2017;30(6):897–904.
Goldstein NS. Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol. 2002;26(2):179–89.
AJCC cancer staging manual. 8th ed. New York: Springer Science+Business Media; 2016. pages cm p.
Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–98.
Cooper HS, Deppisch LM, Gourley WK, Kahn EI, Lev R, Manley PN, et al. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology. 1995;108(6):1657–65.
Cooper HS. Pathologic issues in the treatment of endoscopically removed malignant colorectal polyps. J Natl Compr Cancer Netw. 2007;5(9):991–6.
Cappellesso R, Luchini C, Veronese N, Lo Mele M, Rosa-Rizzotto E, Guido E, et al. Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. Hum Pathol. 2017;65:62–70.
Rosty C, Williamson EJ, Clendenning M, Walters RJ, Win AK, Jenkins MA, et al. Should the grading of colorectal adenocarcinoma include microsatellite instability status? Hum Pathol. 2014;45(10):2077–84.
Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol. 2001;159(6):2107–16.
Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol. 2003;27(11):1407–17.
Truta B, Chen YY, Blanco AM, Deng G, Conrad PG, Kim YH, et al. Tumor histology helps to identify lynch syndrome among colorectal cancer patients. Familial Cancer. 2008;7(3):267–74.
Shia J, Schultz N, Kuk D, Vakiani E, Middha S, Segal NH, et al. Morphological characterization of colorectal cancers in the cancer genome atlas reveals distinct morphology-molecular associations: clinical and biological implications. Mod Pathol. 2017;30(4):599–609.
Hugen N, Verhoeven RH, Lemmens VE, van Aart CJ, Elferink MA, Radema SA, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer. 2015;136(2):333–9.
Park PY, Goldin T, Chang J, Markman M, Kundranda MN. Signet-ring cell carcinoma of the colon: a case report and review of the literature. Case Rep Oncol. 2015;8(3):466–71.
Guzinska-Ustymowicz K, Niewiarowska K, Pryczynicz A. Invasive micropapillary carcinoma: a distinct type of adenocarcinomas in the gastrointestinal tract. World J Gastroenterol. 2014;20(16):4597–606.
Pyo JS, Sohn JH, Kang G. Medullary carcinoma in the colorectum: a systematic review and meta-analysis. Hum Pathol. 2016;53:91–6.
Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology. 2007;50(1):131–50.
Thelin C, Alquist CR, Engel LS, Dewenter T. Primary clear cell adenocarcinoma of the colon: a case report and review. J La State Med Soc. 2014;166(4):143–8.
Wang W, Li X, Qu G, Leng T, Geng J. Primary clear cell adenocarcinoma of the colon presenting as a huge extracolic mass: a case report. Oncol Lett. 2014;8(4):1873–5.
Barrera-Maldonado CD, Wiener I, Sim S. Clear cell adenocarcinoma of the colon: a case report and review of the literature. Case Rep Oncol Med. 2014;2014:905478.
Furuya Y, Wakahara T, Akimoto H, Kishimoto T, Hiroshima K, Yanagie H, et al. Clear cell adenocarcinoma with enteroblastic differentiation of the ascending colon. J Clin Oncol. 2011;29(22):e647–9.
Oh SK, Kim HW, Kang DH, Choi CW, Choi YY, Lim HK, et al. Primary adenocarcinoma with focal choriocarcinomatous differentiation in the sigmoid colon. Korean J Gastroenterol. 2015;66(5):291–6.
Lino-Silva LS, Salcedo-Hernandez RA, Herrera-Gomez A, Padilla-Rosciano A, Ramirez-Jaramillo M, Herrera-Goepfert RE, et al. Colonic cribriform carcinoma, a morphologic pattern associated with low survival. Int J Surg Pathol. 2015;23(1):13–9.
Wong HH, Chu P. Immunohistochemical features of the gastrointestinal tract tumors. J Gastrointest Oncol. 2012;3(3):262–84.
Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3(3):153–73.
Saad RS, Silverman JF, Khalifa MA, Rowsell C. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol. 2009;17(3):196–201.
Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001;159(6):2239–48.
McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol. 2004;28(6):712–8.
Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC. A new prognostic staging system for rectal cancer. Ann Surg. 2004;240(5):832–9.
Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299–311.
Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A, Puppa G, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer. 2016;115(7):831–40.
Suzuki A, Togashi K, Nokubi M, Koinuma K, Miyakura Y, Horie H, et al. Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33(11):1601–7.
Roxburgh CS, McMillan DC, Richards CH, Atwan M, Anderson JH, Harvey T, et al. The clinical utility of the combination of T stage and venous invasion to predict survival in patients undergoing surgery for colorectal cancer. Ann Surg. 2014;259(6):1156–65.
Betge J, Pollheimer MJ, Lindtner RA, Kornprat P, Schlemmer A, Rehak P, et al. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer. 2012;118(3):628–38.
Cienfuegos JA, Martinez P, Baixauli J, Beorlegui C, Rosenstone S, Sola JJ, et al. Perineural invasion is a major prognostic and predictive factor of response to adjuvant chemotherapy in stage I-II colon cancer. Ann Surg Oncol. 2017;24(4):1077–84.
Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol. 2003;84(3):127–31.
Dawson H, Kirsch R, Driman DK, Messenger DE, Assarzadegan N, Riddell RH. Optimizing the detection of venous invasion in colorectal cancer: the Ontario, Canada, experience and beyond. Front Oncol. 2014;4:354.
Kirsch R, Messenger DE, Riddell RH, Pollett A, Cook M, Al-Haddad S, et al. Venous invasion in colorectal cancer: impact of an elastin stain on detection and interobserver agreement among gastrointestinal and nongastrointestinal pathologists. Am J Surg Pathol. 2013;37(2):200–10.
Jin M, Roth R, Rock JB, Washington MK, Lehman A, Frankel WL. The impact of tumor deposits on colonic adenocarcinoma AJCC TNM staging and outcome. Am J Surg Pathol. 2015;39(1):109–15.
Rock JB, Washington MK, Adsay NV, Greenson JK, Montgomery EA, Robert ME, et al. Debating deposits: an interobserver variability study of lymph nodes and pericolonic tumor deposits in colonic adenocarcinoma. Arch Pathol Lab Med. 2014;138(5):636–42.
Ueno H, Mochizuki H, Hashiguchi Y, Ishiguro M, Miyoshi M, Kajiwara Y, et al. Extramural cancer deposits without nodal structure in colorectal cancer: optimal categorization for prognostic staging. Am J Clin Pathol. 2007;127(2):287–94.
Frederick LG, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer staging manual. New York: Springer; 2013.
Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK. AJCC cancer staging atlas: a companion to the seventh editions of the AJCC cancer staging manual and handbook. New York: Springer; 2012.
Lord AC, D'Souza N, Pucher PH, Moran BJ, Abulafi AM, Wotherspoon A, et al. Significance of extranodal tumour deposits in colorectal cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;82:92–102.
Li J, Yang S, Hu J, Liu H, Du F, Yin J, et al. Tumor deposits counted as positive lymph nodes in TNM staging for advanced colorectal cancer: a retrospective multicenter study. Oncotarget. 2016;7(14):18269–79.
Nakanishi Y, LeVea C, Dibaj S, Habib F, Cheney R, Kanehira K. Reappraisal of serosal invasion in patients with T3 colorectal cancer by elastic stain: clinicopathologic study of 139 surgical cases with special reference to peritoneal elastic lamina invasion. Arch Pathol Lab Med. 2016;140(1):81–5.
Chen JH, Borges M. Histopathology and enhanced detection of tumor invasion of peritoneal membranes. PLoS One. 2017;12(3):e0173833.
Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology. 1997;112(4):1096–102.
Min BS, Kim NK, Pyo JY, Kim H, Seong J, Keum KC, et al. Clinical impact of tumor regression grade after preoperative chemoradiation for locally advanced rectal cancer: subset analyses in lymph node negative patients. J Korean Soc Coloproctol. 2011;27(1):31–40.
Biondo S, Navarro M, Marti-Rague J, Arriola E, Pares D, Del Rio C, et al. Response to neoadjuvant therapy for rectal cancer: influence on long-term results. Color Dis. 2005;7(5):472–9.
Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002;94(4):1121–30.
Fernandez-Acenero MJ, Estrada Munoz L, Sastre Varela J, Corona Sanchez JA, Diaz Del Arco C, Garcia Paredes B, et al. Prognostic influence of histopathological regression patterns in rectal adenocarcinoma receiving neoadjuvant therapy. J Gastrointest Oncol. 2017;8(1):49–54.
Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016;48(3):998–1009.
Santos MD, Silva C, Rocha A, Matos E, Nogueira C, Lopes C. Prognostic value of mandard and dworak tumor regression grading in rectal cancer: study of a single tertiary center. ISRN Surg. 2014;2014:310542.
Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19–23.
Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–6.
Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC, et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum. 2002;45(8):1051–6.
Jang S, Hong M, Shin MK, Kim BC, Shin HS, Yu E, et al. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. Hum Pathol. 2017;65:21–30.
Foltran L, De Maglio G, Pella N, Ermacora P, Aprile G, Masiero E, et al. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncol. 2015;11(4):629–40.
Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016;66(5):370–4.
Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Oncol Pract. 2017;13(5):333–7.
Cejas P, Lopez-Gomez M, Aguayo C, Madero R, Moreno-Rubio J, de Castro CJ, et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. Curr Cancer Drug Targets. 2012;12(2):124–31.
Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30(24):2956–62.
Sylvester BE, Vakiani E. Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. J Gastrointest Oncol. 2015;6(6):668–75.
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.
Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13–21.
Lunke S, Lee B, Kranz S, Gibbs P, Waring P, Christie M. Intratumorous heterogeneity for RAS mutations in a treatment-naive colorectal tumour. J Clin Pathol. 2017;70(8):720–3.
Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. Cosmic 2005. Br J Cancer. 2006;94(2):318–22.
Juarez M, Egoavil C, Rodriguez-Soler M, Hernandez-Illan E, Guarinos C, Garcia-Martinez A, et al. KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia. PLoS One. 2017;12(9):e0184937.
Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205(12):858–62.
Scartozzi M, Giampieri R, Aprile G, Iacono D, Santini D, dell’Aquila E, et al. The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. Expert Rev Mol Diagn. 2015;15(8):979–87.
Estrella JS, Tetzlaff MT, Bassett RL Jr, Patel KP, Williams MD, Curry JL, et al. Assessment of BRAF V600E status in colorectal carcinoma: tissue-specific discordances between immunohistochemistry and sequencing. Mol Cancer Ther. 2015;14(12):2887–95.
Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322–30.
Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer. 2010;46(15):2788–98.
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.
Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890–6.
Passardi A, Canale M, Valgiusti M, Ulivi P. Immune checkpoints as a target for colorectal cancer treatment. Int J Mol Sci. 2017;18(6):1–12.
Joost P, Veurink N, Holck S, Klarskov L, Bojesen A, Harbo M, et al. Heterogeneous mismatch-repair status in colorectal cancer. Diagn Pathol. 2014;9:126.
Overbeek LI, Ligtenberg MJ, Willems RW, Hermens RP, Blokx WA, Dubois SV, et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol. 2008;32(8):1246–51.
Kumarasinghe AP, de Boer B, Bateman AC, Kumarasinghe MP. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material. Pathology. 2010;42(5):414–20.
Yantiss RK. Gastrointestinal pathology: common questions and diagnostic dilemmas, an issue of surgical pathology clinics, E-Book. Philadelphia: Elsevier Health Sciences; 2017.
Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012;49(3):151–7.
Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, et al. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome. Mod Pathol. 2017;30(3):440–7.
Shimada Y, Yagi R, Kameyama H, Nagahashi M, Ichikawa H, Tajima Y, et al. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Hum Pathol. 2017;66:1–9.
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;17(4):1206.
Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.
Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer. 2013;108(3):668–75.
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46.
Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562–70.
Lee WS, Park YH, Lee JN, Baek JH, Lee TH, Ha SY. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med. 2014;3(3):674–80.
Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481–91.
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008;134(4):988–97.
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, et al. Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. Eur J Cancer. 2017;84:290–303.
Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51.
Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2013;20(3):946–55.
Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–8.
Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8(327):327ra26.
Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232(2):199–209.
Hynes SO, Coleman HG, Kelly PJ, Irwin S, O’Neill RF, Gray RT, et al. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. Histopathology. 2017;71(1):12–26.
Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62. quiz 63.
Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet. 2014;86(6):510–20.
Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32(19):2001–9.
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017;3(4):464–71.
Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032–7.
DeRycke MS, Gunawardena S, Balcom JR, Pickart AM, Waltman LA, French AJ, et al. Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. Mol Genet Genomic Med. 2017;5(5):553–69.
Rey JM, Ducros V, Pujol P, Wang Q, Buisine MP, Aissaoui H, et al. Improving mutation screening in patients with colorectal cancer predisposition using next-generation sequencing. J Mol Diagn. 2017;19(4):589–601.
Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, et al. High-grade neuroendocrine colorectal carcinomas: a retrospective study of 100 patients. Clin Colorectal Cancer. 2016;15(2):e1–7.
Estrella JS, Taggart MW, Rashid A, Abraham SC. Low-grade neuroendocrine tumors arising in intestinal adenomas: evidence for alterations in the adenomatous polyposis coli/beta-catenin pathway. Hum Pathol. 2014;45(10):2051–8.
Salaria SN, Abu Alfa AK, Alsaigh NY, Montgomery E, Arnold CA. Composite intestinal adenoma-microcarcinoid clues to diagnosing an under-recognised mimic of invasive adenocarcinoma. J Clin Pathol. 2013;66(4):302–6.
Winburn GB. Multiple rectal carcinoids: a case report. Am Surg. 1998;64(12):1200–3.
Park CS, Lee SH, Kim SB, Kim KO, Jang BI. Multiple rectal neuroendocrine tumors: report of five cases. Korean J Gastroenterol. 2014;64(2):103–9.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
Lee SH, Kim BC, Chang HJ, Sohn DK, Han KS, Hong CW, et al. Rectal neuroendocrine and L-cell tumors: diagnostic dilemma and therapeutic strategy. Am J Surg Pathol. 2013;37(7):1044–52.
Federspiel BH, Burke AP, Sobin LH, Shekitka KM. Rectal and colonic carcinoids. A clinicopathologic study of 84 cases. Cancer. 1990;65(1):135–40.
Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer. 2012;3:292–302.
Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology. 2008;87(1):31–9.
Ford MM. Neuroendocrine tumors of the colon and rectum. Dis Colon Rectum. 2017;60(10):1018–20.
Kasuga A, Chino A, Uragami N, Kishihara T, Igarashi M, Fujita R, et al. Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution. J Gastroenterol Hepatol. 2012;27(12):1801–7.
Weinstock B, Ward SC, Harpaz N, Warner RR, Itzkowitz S, Kim MK. Clinical and prognostic features of rectal neuroendocrine tumors. Neuroendocrinology. 2013;98(3):180–7.
de Mestier L, Brixi H, Gincul R, Ponchon T, Cadiot G. Updating the management of patients with rectal neuroendocrine tumors. Endoscopy. 2013;45(12):1039–46.
Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M, et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol. 2017;30(4):610–9.
Bernick PE, Klimstra DS, Shia J, Minsky B, Saltz L, Shi W, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47(2):163–9.
Takizawa N, Ohishi Y, Hirahashi M, Takahashi S, Nakamura K, Tanaka M, et al. Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor. Hum Pathol. 2015;46(12):1890–900.
Karkouche R, Bachet JB, Sandrini J, Mitry E, Penna C, Cote JF, et al. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol. 2012;24(12):1430–7.
Vanacker L, Smeets D, Hoorens A, Teugels E, Algaba R, Dehou MF, et al. Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment. Anticancer Res. 2014;34(10):5517–21.
Scardoni M, Vittoria E, Volante M, Rusev B, Bersani S, Mafficini A, et al. Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components. Neuroendocrinology. 2014;100(4):310–6.
Sahnane N, Furlan D, Monti M, Romualdi C, Vanoli A, Vicari E, et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 2015;22(1):35–45.
Shen C, Yin Y, Chen H, Tang S, Yin X, Zhou Z, et al. Neuroendocrine tumors of colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European Neuroendocrine Tumor Society staging systems. Oncotarget. 2017;8(13):22123–34.
Chagpar R, Chiang YJ, Xing Y, Cormier JN, Feig BW, Rashid A, et al. Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems. Ann Surg Oncol. 2013;20(4):1170–8.
Voltaggio L, Montgomery EA. Gastrointestinal tract spindle cell lesions--just like real estate, it's all about location. Mod Pathol. 2015;28(Suppl 1):S47–66.
Charalampakis V, Stamatiou D, Christodoulakis M, Kafousi M, Chryssou E, de Bree E, et al. Large presacral tailgut cyst with a carcinoid tumor in a male: report of a case. Surg Today. 2014;44(5):961–6.
Manco G, Giliberti G, Rolando G, Gelsomino F, Zunarelli E, Rossi A. Malignant transformation of a tailgut cyst. Ann Ital Chir. 2017;6
Patil P, Jibhkate SN, Pawar V, Valand A. Adenocarcinoma arising in tailgut cyst: a rare case. Indian J Pathol Microbiol. 2014;57(2):341–2.
Prasad AR, Amin MB, Randolph TL, Lee CS, Ma CK. Retrorectal cystic hamartoma: report of 5 cases with malignancy arising in 2. Arch Pathol Lab Med. 2000;124(5):725–9.
Frizelle FA, Hobday KS, Batts KP, Nelson H. Adenosquamous and squamous carcinoma of the colon and upper rectum: a clinical and histopathologic study. Dis Colon Rectum. 2001;44(3):341–6.
Kiyani A, Coyle WJ, Bao F. A rare case of primary rectal squamous cell carcinoma diagnosed by endoscopic ultrasound. J Gastrointest Oncol. 2017;8(4):E56–E9.
Yeh J, Hastings J, Rao A, Abbas MA. Squamous cell carcinoma of the rectum: a single institution experience. Tech Coloproctol. 2012;16(5):349–54.
Williams GT, Blackshaw AJ, Morson BC. Squamous carcinoma of the colorectum and its genesis. J Pathol. 1979;129(3):139–47.
Audeau A, Han HW, Johnston MJ, Whitehead MW, Frizelle FA. Does human papilloma virus have a role in squamous cell carcinoma of the colon and upper rectum? Eur J Surg Oncol. 2002;28(6):657–60.
Kobayashi S, Sasaki M, Goto T, Asakage N, Sekine M, Suzuki T, et al. Endometrioid adenocarcinoma arising from endometriosis of the rectosigmoid. Dig Endosc. 2010;22(1):59–63.
Okazawa Y, Takahashi R, Mizukoshi K, Takehara K, Ishiyama S, Sugimoto K, et al. A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. Int J Surg Case Rep. 2014;5(12):979–83.
Verma R, Osborn S, Horgan K. Endometrioid adenocarcinoma of caecum causing intussusception. Case Rep Surg. 2013;2013:714126.
Wakeley CP. The position of the vermiform appendix as ascertained by an analysis of 10,000 cases. J Anat. 1933;67(Pt 2):277–83.
Bjerke K, Brandtzaeg P, Rognum TO. Distribution of immunoglobulin producing cells is different in normal human appendix and colon mucosa. Gut. 1986;27(6):667–74.
Stanley MW, Cherwitz D, Hagen K, Snover DC. Neuromas of the appendix. A light-microscopic, immunohistochemical and electron-microscopic study of 20 cases. Am J Surg Pathol. 1986;10(11):801–15.
Mills SE. Histology for pathologists. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. xi. 1272 p.
Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum. 1998;41(1):75–80.
Teixeira FJR Jr, Couto Netto SDD, Akaishi EH, Utiyama EM, Menegozzo CAM, Rocha MC. Acute appendicitis, inflammatory appendiceal mass and the risk of a hidden malignant tumor: a systematic review of the literature. World J Emerg Surg. 2017;12:12.
McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer. 2002;94(12):3307–12.
McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum. 2005;48(12):2264–71.
Das R, Cantor JP, Vu TQ. Two concurrent appendiceal neoplasms in an elderly patient: a case report. Int J Surg Case Rep. 2017;40:124–6.
Dellaportas D, Vlahos N, Polymeneas G, Gkiokas G, Dastamani C, Carvounis E, et al. Collision tumor of the appendix: mucinous cystadenoma and carcinoid. A case report. Chirurgia (Bucur). 2014;109(6):843–5.
Ruoff C, Hanna L, Zhi W, Shahzad G, Gotlieb V, Saif MW. Cancers of the appendix: review of the literatures. ISRN Oncol. 2011;2011:728579.
Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol. 1998;93(3):422–8.
Tomioka K, Fukoe Y, Lee Y, Lee M, Wada Y, Aoki T, et al. Primary neuroendocrine carcinoma of the appendix: a case report and review of the literature. Anticancer Res. 2013;33(6):2635–8.
O’Kane AM, O’Donnell ME, Shah R, Carey DP, Lee J. Small cell carcinoma of the appendix. World J Surg Oncol. 2008;6:4.
Warkel RL, Cooper PH, Helwig EB. Adenocarcinoid, a mucin-producing carcinoid tumor of the appendix: a study of 39 cases. Cancer. 1978;42(6):2781–93.
Burke AP, Sobin LH, Federspiel BH, Shekitka KM, Helwig EB. Goblet cell carcinoids and related tumors of the vermiform appendix. Am J Clin Pathol. 1990;94(1):27–35.
Kelly KJ. Management of Appendix Cancer. Clin Colon Rectal Surg. 2015;28(4):247–55.
Roggo A, Wood WC, Ottinger LW. Carcinoid tumors of the appendix. Ann Surg. 1993;217(4):385–90.
Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151–60.
Amr B, Froghi F, Edmond M, Haq K, Thengungal KR. Management and outcomes of appendicular neuroendocrine tumours: retrospective review with 5-year follow-up. Eur J Surg Oncol. 2015;41(9):1243–6.
Krumpelmann K, Hansen T, Fried-Proell W, Habekost M, Flieger D, Sommer S, et al. Rectal goblet cell carcinoid. Primary tumor or metastasis? Pathologe. 2013;34(1):65–9.
Costantini M, Montalti R, Rossi G, Luisa L, Masetti M, Di Benedetto F, et al. Adenocarcinoid tumor of the extrahepatic biliary tract. Int J Surg Pathol. 2008;16(4):455–7.
Tang LH, Shia J, Soslow RA, Dhall D, Wong WD, O'Reilly E, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008;32(10):1429–43.
Taggart MW, Abraham SC, Overman MJ, Mansfield PF, Rashid A. Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch Pathol Lab Med. 2015;139(6):782–90.
Lee LH, McConnell YJ, Tsang E, Zerhouni S, Speers C, Kennecke H, et al. Simplified 2-tier histologic grading system accurately predicts outcomes in goblet cell carcinoid of the appendix. Hum Pathol. 2015;46(12):1881–9.
Wen KW, Hale G, Shafizadeh N, Hosseini M, Huang A, Kakar S. Appendiceal goblet cell carcinoid: common errors in staging and clinical interpretation with a proposal for an improved terminology. Hum Pathol. 2017;65:187–93.
Shenoy S. Goblet cell carcinoids of the appendix: tumor biology, mutations and management strategies. World J Gastrointest Surg. 2016;8(10):660–9.
Olsen IH, Holt N, Langer SW, Hasselby JP, Gronbaek H, Hillingso J, et al. Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients. PLoS One. 2015;10(2):e0117627.
Taggart MW, Galbincea J, Mansfield PF, Fournier KF, Royal RE, Overman MJ, et al. High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol. 2013;37(8):1192–200.
Carr NJ, McCarthy WF, Sobin LH. Epithelial noncarcinoid tumors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer. 1995;75(3):757–68.
Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol. 2009;33(10):1425–39.
Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27(8):1089–103.
Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, Gonzalez-Moreno S, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26.
Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847–58.
Lamps LW, Gray GF Jr, Dilday BR, Washington MK. The coexistence of low-grade mucinous neoplasms of the appendix and appendiceal diverticula: a possible role in the pathogenesis of pseudomyxoma peritonei. Mod Pathol. 2000;13(5):495–501.
Yantiss RK, Shia J, Klimstra DS, Hahn HP, Odze RD, Misdraji J. Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol. 2009;33(2):248–55.
Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19(12):1390–408.
Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–5.
Rabban JT, Vohra P, Zaloudek CJ. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia. Am J Surg Pathol. 2015;39(1):35–51.
Bradley RF, Stewart JH, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30(5):551–9.
Davison JM, Choudry HA, Pingpank JF, Ahrendt SA, Holtzman MP, Zureikat AH, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014;27(11):1521–39.
Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA, et al. Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade. World J Gastrointest Oncol. 2017;9(9):354–62.
Shetty S, Natarajan B, Thomas P, Govindarajan V, Sharma P, Loggie B. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg. 2013;79(11):1171–6.
Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013;257(6):1072–8.
Sirintrapun SJ, Blackham AU, Russell G, Votanopoulos K, Stewart JH, Shen P, et al. Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. Hum Pathol. 2014;45(8):1597–604.
Misdraji J, Lauwers GY, Irving JA, Batts KP, Young RH. Appendiceal or cecal endometriosis with intestinal metaplasia: a potential mimic of appendiceal mucinous neoplasms. Am J Surg Pathol. 2014;38(5):698–705.
Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201.
Arnason T, Kamionek M, Yang M, Yantiss RK, Misdraji J. Significance of proximal margin involvement in low-grade appendiceal mucinous neoplasms. Arch Pathol Lab Med. 2015;139(4):518–21.
Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett BM. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol. 1999;154(6):1849–55.
Kabbani W, Houlihan PS, Luthra R, Hamilton SR, Rashid A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol. 2002;15(6):599–605.
Zauber P, Berman E, Marotta S, Sabbath-Solitare M, Bishop T. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix. Scand J Gastroenterol. 2011;46(7–8):869–74.
Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013;18(12):1270–7.
Singhi AD, Davison JM, Choudry HA, Pingpank JF, Ahrendt SA, Holtzman MP, et al. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Hum Pathol. 2014;45(8):1737–43.
Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, et al. Correction: genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med. 2014;6(7):53.
Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer. 2016;122(2):213–21.
Chua TC, Chong CH, Liauw W, Morris DL. Approach to rectal cancer surgery. Int J Surg Oncol. 2012;2012:247107.
Benedix F, Reimer A, Gastinger I, Mroczkowski P, Lippert H, Kube R, et al. Primary appendiceal carcinoma--epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol. 2010;36(8):763–71.
Perez Montiel D, Arispe Angulo K, Cantu-de Leon D, Bornstein Quevedo L, Chanona Vilchis J, Herrera Montalvo L. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic. Ann Diagn Pathol. 2015;19(4):249–52.
Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol. 2001;25(9):1121–33.
Kaneko M, Kawai K, Murono K, Nishikawa T, Sasaki K, Otani K, et al. Giant gastrointestinal stromal tumor of the vermiform appendix: a case report. Mol Clin Oncol. 2017;7(3):399–403.
Chun JM, Lim KH. Gastrointestinal stromal tumor of the vermiform appendix mimicking Meckel's diverticulum: case report with literature review. Int J Surg Case Rep. 2016;21:20–2.
Guo L, He K, Xu X, Li G, Li Z, Xia Y, et al. Giant appendiceal neurofibroma in von Recklinghausen's disease: a case report and literature review. Oncol Lett. 2014;8(5):1957–60.
Natalia C, Koh CE, Lee PJ. Giant appendiceal leiomyosarcoma: a rare and unusual tumour. Case Rep Surg. 2011;2011:384762.
Suh SW, Park JM, Choi YS, Cha SJ, Chang IT, Kim BG. Laparoscopic approach to a case of appendicular schwannoma. J Korean Soc Coloproctol. 2010;26(4):302–6.
Matkowskyj KA, Rao MS, Raparia K. Transcription factor E3 protein-positive perivascular epithelioid cell tumor of the appendix presenting as acute appendicitis: a case report and review of the literature. Arch Pathol Lab Med. 2013;137(3):434–7.
Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. 2013;31(12):1569–75.
Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201.
Shiels MS, Kreimer AR, Coghill AE, Darragh TM, Devesa SS. Anal cancer incidence in the United States, 1977-2011: distinct patterns by histology and behavior. Cancer Epidemiol Biomark Prev. 2015;24(10):1548–56.
Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr. 2005;40(4):451–5.
Baricevic I, He X, Chakrabarty B, Oliver AW, Bailey C, Summers J, et al. High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. Eur J Cancer. 2015;51(6):776–85.
Patel HS, Silver AR, Northover JM. Anal cancer in renal transplant patients. Int J Color Dis. 2007;22(1):1–5.
Nagle D. Anal squamous cell carcinoma in the HIV-positive patient. Clin Colon Rectal Surg. 2009;22(2):102–6.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.
Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317(16):973–7.
van de Laar TJ, Richel O. Emerging viral STIs among HIV-positive men who have sex with men: the era of hepatitis C virus and human papillomavirus. Sex Transm Infect. 2017;93(5):368–73.
Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12(5):524–34.
Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am. 2004;13(2):263–75.
Schim van der Loeff MF, Mooij SH, Richel O, de Vries HJ, Prins JM. HPV and anal cancer in HIV-infected individuals: a review. Curr HIV/AIDS Rep. 2014;11(3):250–62.
Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res. 2008;2(1):10–4.
Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–34.
Fenger C, Nielsen VT. Intraepithelial neoplasia in the anal canal. The appearance and relation to genital neoplasia. Acta Pathol Microbiol Immunol Scand A. 1986;94(5):343–9.
Northfelt DW, Swift PS, Palefsky JM. Anal neoplasia. Pathogenesis, diagnosis, and management. Hematol Oncol Clin North Am. 1996;10(5):1177–87.
Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32(1):76–115.
Roma AA, Liu X, Patil DT, Xie H, Allende D. Proposed terminology for anal squamous lesions: its application and interobserver agreement among pathologists in academic and community hospitals. Am J Clin Pathol. 2017;148(1):81–90.
Hickman RA, Bradshaw AD, Cassai N, Neto AG, Zhou D, Fu T, et al. A rare case of anal carcinosarcoma with human papilloma virus infection in both biphasic tumor elements: an immunohistochemical, molecular and ultrastructural study. Papillomavirus Res. 2016;2:164–6.
Kondo R, Hanamura N, Kobayashi M, Seki T, Adachi W, Ishii K. Mucoepidermoid carcinoma of the anal canal: an immunohistochemical study. J Gastroenterol. 2001;36(7):508–14.
Dougherty BG, Evans HL. Carcinoma of the anal canal: a study of 79 cases. Am J Clin Pathol. 1985;83(2):159–64.
Dougherty LS, Hull T. Perineal endometriosis with anal sphincter involvement: report of a case. Dis Colon Rectum. 2000;43(8):1157–60.
Cimino-Mathews A, Sharma R, Illei PB. Detection of human papillomavirus in small cell carcinomas of the anus and rectum. Am J Surg Pathol. 2012;36(7):1087–92.
Chu QD, Vezeridis MP, Libbey NP, Wanebo HJ. Giant condyloma acuminatum (Buschke-Lowenstein tumor) of the anorectal and perianal regions. Analysis of 42 cases. Dis Colon Rectum. 1994;37(9):950–7.
Ackerman LV. Verrucous carcinoma of the oral cavity. Surgery. 1948;23(4):670–8.
Zidar N, Langner C, Odar K, Hosnjak L, Kamaradova K, Daum O, et al. Anal verrucous carcinoma is not related to infection with human papillomaviruses and should be distinguished from giant condyloma (Buschke-Lowenstein tumour). Histopathology. 2017;70(6):938–45.
del Pino M, Bleeker MC, Quint WG, Snijders PJ, Meijer CJ, Steenbergen RD. Comprehensive analysis of human papillomavirus prevalence and the potential role of low-risk types in verrucous carcinoma. Mod Pathol. 2012;25(10):1354–63.
Odar K, Kocjan BJ, Hosnjak L, Gale N, Poljak M, Zidar N. Verrucous carcinoma of the head and neck - not a human papillomavirus-related tumour? J Cell Mol Med. 2014;18(4):635–45.
Wells M, Robertson S, Lewis F, Dixon MF. Squamous carcinoma arising in a giant peri-anal condyloma associated with human papillomavirus types 6 and 11. Histopathology. 1988;12(3):319–23.
Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001;25(7):884–91.
Kong CS, Balzer BL, Troxell ML, Patterson BK, Longacre TA. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol. 2007;31(1):33–43.
Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, et al. Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Ann Oncol. 2016;27(7):1336–41.
Meulendijks D, Tomasoa NB, Dewit L, Smits PH, Bakker R, van Velthuysen ML, et al. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer. 2015;112(8):1358–66.
Boman BM, Moertel CG, O'Connell MJ, Scott M, Weiland LH, Beart RW, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer. 1984;54(1):114–25.
Singh R, Nime F, Mittelman A. Malignant epithelial tumors of the anal canal. Cancer. 1981;48(2):411–5.
AJCC Cancer staging manual. 8th. New York: Springer Science+Business Media; 2016. pages cm p.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116(17):4007–13.
Glynne-Jones R, Rao S. Treatment of the primary tumor in anal canal cancers. Surg Oncol Clin N Am. 2017;26(1):73–90.
Glynne-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows HM, et al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer. 2013;119(4):748–55.
Arora N, Gupta A, Zhu H, Christie A, Meyer JJ, Khan SA, et al. Race- and sex-based disparities in the therapy and outcomes of squamous cell carcinoma of the anus. J Natl Compr Cancer Netw. 2017;15(8):998–1004.
Franklin RA, Giri S, Valasareddy P, Lands LT, Martin MG. Comparative survival of patients with anal adenocarcinoma, squamous cell carcinoma of the anus, and rectal adenocarcinoma. Clin Colorectal Cancer. 2016;15(1):47–53.
Koulos J, Symmans F, Chumas J, Nuovo G. Human papillomavirus detection in adenocarcinoma of the anus. Mod Pathol. 1991;4(1):58–61.
Matalon SA, Mamon HJ, Fuchs CS, Doyle LA, Tirumani SH, Ramaiya NH, et al. Anorectal cancer: critical anatomic and staging distinctions that affect use of radiation therapy. Radiographics. 2015;35(7):2090–107.
Kulkarni MP, Momin YA, Pandav AB, Sulhyan KR. Adenocarcinoma of the anal canal: a report of two cases with review of literature. Indian J Pathol Microbiol. 2016;59(3):404–6.
Hobbs CM, Lowry MA, Owen D, Sobin LH. Anal gland carcinoma. Cancer. 2001;92(8):2045–9.
Sakamoto T, Konishi F, Yoshida T, Yoshinaga Y, Izumo T, Lefor A. Adenocarcinoma arising from an anal gland-report of a case. Int J Surg Case Rep. 2014;5(5):234–6.
Iesalnieks I, Gaertner WB, Glass H, Strauch U, Hipp M, Agha A, et al. Fistula-associated anal adenocarcinoma in Crohn’s disease. Inflamm Bowel Dis. 2010;16(10):1643–8.
Minicozzi A, Borzellino G, Momo R, Steccanella F, Pitoni F, de Manzoni G. Perianal Paget’s disease: presentation of six cases and literature review. Int J Color Dis. 2010;25(1):1–7.
Goldblum JR, Hart WR. Perianal Paget’s disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol. 1998;22(2):170–9.
Sisodia S, Boushey R, Lee G, Marginean C, Gomes MM, Bhattacharya G, et al. Perianal pagetoid intraepithelial carcinoma. Case Rep Gastroenterol. 2017;11(1):109–13.
Sah SP, Kelly PJ, McManus DT, McCluggage WG. Diffuse CK7, CAM5.2 and BerEP4 positivity in pagetoid squamous cell carcinoma in situ (pagetoid Bowen’s disease) of the perianal region: a mimic of extramammary Paget’s disease. Histopathology. 2013;62(3):511–4.
Aytac E, Ozdemir Y, Ozuner G. Long term outcomes of neuroendocrine carcinomas (high-grade neuroendocrine tumors) of the colon, rectum, and anal canal. J Visc Surg. 2014;151(1):3–7.
Surag, Neeralagi C, Prasath A, Kumar P, Reddy B. Small cell carcinoma of anal canal – a rare case report. J Clin Diagn Res. 2016;10(9):PD14–PD5.
Khan M, Dirweesh A, Alvarez C, Conaway H, Moser R. Anal neuroendocrine tumor masquerading as external hemorrhoids: a case report. Gastroenterology Res. 2017;10(1):56–8.
Shia J. An update on tumors of the anal canal. Arch Pathol Lab Med. 2010;134(11):1601–11.
Paterson C, Musselman L, Chorneyko K, Reid S, Rawlinson J. Merkel cell (neuroendocrine) carcinoma of the anal canal: report of a case. Dis Colon Rectum. 2003;46(5):676–8.
Wang X, Bai P, Su H, Luo G, Zhong Z, Zhao X. Management of primary adenocarcinoma of the female urethra: report of two cases and review of the literature. Oncol Lett. 2012;4(5):951–4.
Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664–78.
Ho SP, Tseng HH, King TM, Chow PC. Anal phyllodes tumor in a male patient: a unique case presentation and literature review. Diagn Pathol. 2013;8:49.
Balachandra B, Marcus V, Jass JR. Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist. Histopathology. 2007;50(1):163–74.
Sturiale A, Fabiani B, Naldini G. A rare case of leiomyoma of the internal anal sphincter. Int J Surg Case Rep. 2016;23:4–7.
Carvalho N, Albergaria D, Lebre R, Giria J, Fernandes V, Vidal H, et al. Anal canal gastrointestinal stromal tumors: case report and literature review. World J Gastroenterol. 2014;20(1):319–22.
Fujii T, Morita H, Yamaguchi S, Tsutsumi S, Asao T, Kuwano H. A rare case of granular cell tumor of the anal region: diagnostic difficulty to masses in the anal area. Int Surg. 2014;99(1):45–7.
Sweeney K, Petrelli N, Herrera L, Lopez C, Mittelman A. Cavernous hemangioma of the anus. J Surg Oncol. 1984;27(4):286–8.
Nassif MO, Trabulsi NH, Bullard Dunn KM, Nahal A, Meguerditchian AN. Soft tissue tumors of the anorectum: rare, complex and misunderstood. J Gastrointest Oncol. 2013;4(1):82–94.
Porta E, Cazzaniga A. Lipoma of the anal canal. Minerva Chir. 1979;34(22):1557–60.
Blakely ML, Andrassy RJ, Raney RB, Anderson JR, Wiener ES, Rodeberg DA, et al. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997. J Pediatr Surg. 2003;38(3):347–53.
Val-Bernal JF, Mayorga M, Diego C, Gonzalez-Vela MC. Pedunculated polypoid lymphangioma of the anal canal. Pathol Int. 2008;58(7):442–4.
Tekin K, Sungurtekin U, Aytekin FO, Calli N, Erdem E, Ozden A, et al. Ectopic prostatic tissue of the anal canal presenting with rectal bleeding: report of a case. Dis Colon Rectum. 2002;45(7):979–80.
Leonard D, Beddy D, Dozois EJ. Neoplasms of anal canal and perianal skin. Clin Colon Rectal Surg. 2011;24(1):54–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Taggart, M.W., Foo, W.C., Lee, S.M. (2020). Tumors of the Gastrointestinal System Including the Pancreas. In: Moran, C.A., Kalhor, N., Weissferdt, A. (eds) Oncological Surgical Pathology . Springer, Cham. https://doi.org/10.1007/978-3-319-96681-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-96681-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-96680-9
Online ISBN: 978-3-319-96681-6
eBook Packages: MedicineMedicine (R0)